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The whole of science is nothing more than a refinement of every day 
thinking.    
                                  
 
                                                   By Albert Einstein 
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ABSTRACT 
 
DNA Polymerase (pol) λ is an X family protein sharing 32% amino acid identity to DNA 
pol β. Structural subdomains of DNA pol λ are similar to DNA pol β namely fingers, palm, 
thumb and the 8-kDa 5′-deoxyribose phosphate lyase (dRP lyase) domain. DNA pol λ has 
no proof reading ability since it lacks 3′→5′exonuclease activity and is known to have high 
affinity for deoxyribonucleosidetriphosphates (dNTPs). DNA Pol λ contains all the critical 
residues involved in DNA binding, nucleotide binding, nucleotide selection and catalysis of 
DNA polymerization. On the basis of the biochemical activity DNA pol λ is implicated in 
translesion DNA synthesis (TLS), base excision repair (BER) and non-homologous end 
joining (NHEJ). The most common lesion produced by reactive oxygen species is 7,8-
dihydro-8-oxoguanine (8-oxo-G). This highly mutagenic lesion leads to G>T transversions 
as DNA pol λ can either incorporate dATP or dCTP opposite an 8-oxo-G lesion. DNA pol 
λ is very efficient in performing error-free TLS past an 8-oxo-G along with auxiliary 
proteins proliferating cell nuclear antigen (PCNA) and replication protein A (RP-A). The 
auxiliary proteins PCNA and RP-A act as molecular switches to coordinate the pol 
selection in 8-oxo-G repair.  
 
The aim of the thesis part 1 was to understand the role of DNA pol λ as a translesion repair 
enzyme over the O-6-methylguanine (O-6-mG) lesion along with auxiliary proteins PCNA 
and RP-A. In order to understand the role of Tyr505, the highly conserved catalytic residue 
over O-6-mG, we performed a single hydrophobic amino acid substitution. The data 
obtained lead to the conclusion that the mutation allows for an error free TLS over O-6-
mG. This work contributes to the understanding that a small change in the local 
environment, can lead to alteration in the hydrogen-bonding pattern, thus remarkably 
altering the pol fidelity.  
 
 In part 2 the role of the functional interactions between the Werner syndrome protein 
(WRN) and DNA pol λ was investigated. Aging is associated with damage accumulation 
produced by reactive oxygen species (ROS) in the genome and increased cancer incidence. 
8-oxo-G being the most commonly produced lesion by ROS is repaired by DNA pol λ via 
 5 
the BER pathway. WRN is a RECQ family of DNA helicase and is also known to be 
associated with an inherited diseases paving way to premature aging, increased cancer 
incidence and genomic instability. A specific recruitment of WRN and DNA pol λ from 
whole cell extracts to the A:8-oxo-G DNA template was identified in vitro and in vivo data 
demonstrate a functional interaction between DNA pol λ and WRN. The interacting 
interface of DNA pol λ was identified in its pol β like core domain. Cells exposed to 
oxidative stress enhanced the WRN and DNA pol λ association with a strong nuclear co-
localization signal. These results present strong evidence for the involvement of WRN in 
oxidative DNA damage repair. 
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ZUSAMMENFASSUNG 
 
DNA Polymerase (Pol) λ ist ein Protein der X Familie, welches 32% Sequenzidentität mit 
DNA Pol β aufweist. Strukturelle Subdomänen von DNA Pol λ haben Ähnlichkeit zu den 
Finger-, Handfläche-, Daumen- und der 8 kDa 5'-Deoxyribosephosphat Lyase (dRP Lyase) 
Domänen von DNA Pol β. DNA Pol λ hat keine Korrekturfähigkeit, weil ihr die 3'->5' 
Exonukleaseaktivität fehlt, und sie zeigt hohe Affinität zu Desoxyribonucleosidtriphoshaten 
(dNTPs). Sie enthält alle notwendigen Reste, welche an der Bindung und Selektion von 
DNA und Nukleotiden und an der Katalyse der DNA Polymerisierung beteiligt sind. 
Basierend auf biochemischen Experimenten wird eine Rolle von DNA Pol λ in der 
Transläsions-DNA-Synthese (TLS), Basen- Exzsions Reparatur (BER) und der 
Verknüpfung von nichthomologen Enden vermutet. Die häufigste Läsion, welche durch 
reaktive Sauerstoffspezies hervorgerufen wird, ist 7,8-Dihydro-8-oxoguanin (8-oxo-G). 
Diese höchst mutagene Läsion führt zu G>T Transversionen, weil DNA Pol λ sowohl 
dATP als auch dCTP im DNA Strang gegenüber der 8-oxo-G Läsion einfügen kann. 
Zusammen mit den Hilfsproteinen “Proliferating Cell Nuclear Antigen” (PCNA) und 
“Replication Protein” (RP-A) kann DNA Pol λ sehr effizient fehlerfreie TLS ausführen. 
Dies geschieht meist durch BER. Die beiden Hilfsproteine fungieren dabei als molekulare 
Schalter, welche die Selektion der DNA pol in der 8-oxo-G Reparatur koordinieren. 
 
Das Ziel des ersten Teils dieser Doktorarbeit war die Funktion von DNA Pol λ als 
Reparaturenzym für die O-6-Methylguanin (O-6-mG) Läsion in Kooperation mit PCNA 
und RP-A zu untersuchen. Um die Rolle des höchst konservierten katalytischen Rests 
Tyr505 zu ergründen, wuvde wir eine einzelne hydrophobe Aminosäuresubstitution von 
Tyr505Met im aktiven Zentrum durchgeführt. Unsere Beobachtungen haben zum Schluss 
geführt, dass diese Mutation eine fehlerfreie TLS von O-6-mG erlaubt. Damit trägt diese 
Arbeit zur Sicht bei, dass eine kleine Veränderung, welche das Wasserstoffbrückenmuster 
verändert, die DNA Pol genanigkeit bemerkenswert beeinflussen kann. 
 
Im zweiten Teil wurde wir die Rolle der funktionalen Interaktion zwischen dem Werner-
Syndrom Protein (WRN) und DNA Pol λ untersucht. Das Altern ist mit einer Ansammlung 
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von Beschädigungen des Genoms durch reaktive Sauerstoffspezies (ROS) und einem 
erhöhten Auftreten von Krebserkrankungen verbunden. 8-oxo-G ist die häufigste durch 
ROS hervorgerufene Läsion und wird via BER von DNA Pol λ repariert. WRN ist ein 
Protein der RecQ Familie von DNA Helicasen und wird assoziiert mit Erbkrankheiten, 
welche vorzeitiges Altern, erhöhte Krebshäufigkeit und Genominstabilität hervorrufen. 
Eine Rekrutierung von WRN und DNA Pol λ aus Zellextrakten ans A:8-oxo-G DNA 
Templat konnte nachgewiesen werden. In vitro und in vivo Daten zeigen eine funktionale 
Interaktion zwischen DNA Pol λ und WRN. Als interagierende Berührungsfläche von DNA 
Pol λ wurde ihre Kerndomäne identifiziert, welche Ähnlichkeit mit DNA Pol β aufweist. 
Zellen welche oxidativem Stress ausgesetzt sind verstärken die Assoziation zwischen WRN 
und DNA Pol λ, welche dabei eine starke Kolokalisation im Zellkern zeigen. Diese 
Resultate stellen einen starken Beweis dar für die Einbindung von WRN in der Reparatur 
von oxidativen Schäden an der DNA. 
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Part I 
 
AIM 
 
DNA lesions that are constantly produced by exogenous and endogenous chemicals and 
other agents can result in uncontrolled duplication of cells and therefore leading to cancer. 
The ability of certain DNA polymerases to bypass such toxic lesions accurately is required 
to maintain genomic stability. In context to the above scenario the aim of part 1 of this 
thesis project was to study translesion synthesis by DNA polymerase λ, a member of the X-
family DNA polymerase, over the highly toxic O-6-methylguanine lesion. Single 
hydrophobic substitution mutants of the active site residues were constructed to unveil its 
possible role in nucleotide selectivity opposite the lesion. This was extended a step forward 
to understand the role of the auxiliary proteins proliferating cell nuclear antigen (PCNA) 
and replication protein (RP-A) in the bypass of the O-6-methylguanine lesion. 
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INTRODUCTION 
 
O-6-methylguanine (O-6-mG) is a minor modification that leads to highly mutagenic DNA 
adduct (1). Exogenous compounds like N-methyl-N-nitrosourea, methyl methane sulfonate 
and N-methyl-N′-nitro-nitrosoguanine, endogenous biochemical compounds like S-
adenosylmethionine and metabolically nitrosated amines and amides such as betaine and 
choline can produce O-6-methylguanine (2-4). Compounds like nitrates and nitrites found 
in food and beverages can form methylating agents in cells (5).  
 
Methylation of DNA  
 
Twelve different sites on DNA bases are attacked, by most methylating agents, including 
all the exocyclic oxygen and most ring nitrogens. They can also methylate oxygen atoms in 
the phosphate of the sugar-phosphate backbone, thereby generating methylphosphotriesters 
(6,7). O-6-mG DNA lesions are induced by SN1 or SN2 mode of nucleophilic substitution 
reactions. Methylating agents decide the proportion of alkylation that occurs at different 
sites of the DNA bases. SN1 agents, such as N-methyl-N-nitrosourea and N-methyl-N′-
nitro-nitrosoguanine are highly mutagenic because they react more readily with the 
oxygens in DNA to generate the main mispairing adduct O-6-mG and also other minor 
adducts (8). DNA polymerases (pols) stall at these lesions and insert the incorrect base 
thymine at a frequency of more than 90% during replication (9). Due to the mispairing, 
with thymine during DNA replication GC→AT transition mutations occurs (10). 
 
Repair of O-6-methyl Guanine  
 
The O-6-mG DNA lesion is recognized and repaired by the methyl guanine DNA 
methyltransferase (MGMT) protein and by DNA-mismatch repair (MMR) pathway.  
 
O-6-methylguanine methyltransferase (MGMT): 
 
The O-6-mG adduct in DNA is removed by an ubiquitous and unique repair protein, O-6-
mG DNA methyltransferease (MGMT; DNA-O-6-methylguanine protein-L-cysteine S-
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methyltransferase, EC 2.1.1.63) present in most species (11). Unlike other enzymes this 
protein transfers the methyl group from the lesion in a stoichiometic second–order reaction 
(12).  The methyl lesion is covalently bound to a cysteine residue within the active site of 
the protein and is therefore called  a “suicidal protein” (13) (Figure 1.1).  
 
 
Figure 1: Reaction mechanism of MGMT. The O-6-alkylguanine DNA alkyltransferase protein scans 
double-stranded DNA for alkylation at the O6 position of guanine. Covalent transfer of the alkyl group (in the 
figure shown as methyl group, CH3 group) to the conserved active site cysteine inactivates the MGMT protein 
and restores the guanine to normal. Reproduced from Gerson, S.L, Nature Reviews Cancer, 4, 943-955 
(2004).  
 
 
In mammals, MGMT expression is highly regulated in different tissues and cell lines (14-
16). It functions as an alkyl acceptor of O-6-mG. MGMT can also repair O-6-mG in open 
chromatin during transcription and replication  as well as in condensed DNA. It is known 
that Mgmt-knockout mice (Mgmt-/-) are more sensitive to methylating agents than the 
wild-type (wt) mice (Mgmt+/+) counterparts (17,18). This illustrates the importance of 
MGMT in the repair of O-6-mG lesions.  
 
Mismatch repair (MMR) and O-6-methyl Guanine lesion: 
 
During DNA replication, thymine is mispaired to O-6-mG by replicative DNA pols. If the 
O-6-mG lesion is not repaired by MGMT a O-6-mG:T mismatch, can result leading to a 
subsequent mutation on the daughter strand. The O-6-mG:T mispair lesion is then 
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recognized by the MMR proteins MutSα and MutSβ and hence the MMR repair machinary 
removes the dT (19). However, the O-6-mG, during the next around of replication will 
again pair with thymine, allowing for repeated binding of the MMR proteins. Therefore the 
processing of O-6-mG is aberrant. This leads to apoptosis resulting from several rounds of 
repair and single-strand breaks. However there are recent evidences for the recruitment of 
the DNA damage signaling kinase ATM and/or ATR to the site of O-6-mG:T after 
recognition by the MMR proteins (20). These proteins then directly signal for cell cycle 
checkpoints and apoptosis. Exonuclease 1 plays a vital role in the MMR pathway and is 
known to be involved in eliciting apoptosis (21) (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. DNA repair mechanisms of a O-6-mG damage. After a O-6-mG alterations possible outcomes 
include: (1) reapir by MGMT. (2) apoptosis (3) methylation tolerence and induction of mutations. The later 
outcome is predicted to be responsible for transformation. For details see text. Reproduced from J. M. Allan 
& L. B.Travis, Nature Reviews Cancer, 5, 943-955 (2005).  
 
 
DNA polymerases and O-6-methyl Guanine lesions: 
 
Past evidences have proven that O-6-mG lesion blocked the E.coli DNA pol I Klenow 
fragment. Eukaryotic DNA pol α, which is involved in lagging strand DNA synthesis is 
strongly blocked one base before the lesion, suggesting an inhibition of nucleotide 
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incorporation opposite the lesion (22,23). The Y family translesion DNA pol ι and κ 
produce mainly one nucleotide base incorporation, whereas as DNA pol η could bypass O-
6-mG (24,25). Steady state kinetic analysis indicated a similar efficiency of insertion 
opposite the lesion for dCTP and dTTP by DNA pols η and κ. However DNA pol ι showed 
preferential incorporation for dTTP (26,27). DNA pol ζ is highly inefficient at inserting 
nucleotide opposite the lesion, but can efficiently extend from the nucleotide inserted 
opposite the lesion. DNA pol β, together with G:T-specific thymine-DNA glycosylase was 
shown to be involved in the futile cycling at the O-6-mG lesions along with MutSα (22,25). 
Processing of O-6-mG by mismatch correction also requires PCNA and DNA pol δ and/or 
ε (28). The above studies indicated that all known DNA pols incorporate the incorrect 
thymine at equal or higher frequency than the correct cytosine opposite O-6-mG.  
 
DNA polymerases  
 
Based on sequence homologies and structural similarities, DNA pols are grouped in the 
seven different families. A, B, C, D, X, Y and reverse transcriptase (RT) (29). The family X 
of DNA pols contain DNA pol β, λ, µ and terminal transferase (Tdt). X family DNA pols 
are small proteins found in vertebrates and are known to function in DNA repair (30). 
 
DNA polymerase λ: 
 
Human DNA pol λ is a 68kDa protein encoded by 575 amino acid by the POLL gene and 
maps to chromosome 10q23. DNA pol λ shares 32% amino acid sequence homology to 
human DNA pol β (31,32). DNA pol λ is a single subunit protein, which catalyzes DNA 
synthesis in a template dependent manner and has no associated 3′→5′ exonuclease activity 
(33). The N-terminal BRCT domain is involved in protein-protein interactions; the pol β 
like domain is the catalytic core and a serine-proline rich region (34), which is suggested to 
be a target for posttranslational modification like phosphorylation, known to maintain 
protein stability (34-36). The catalytic core is composed of an N-terminal 8kDa domain and 
a polymerase domain including the fingers, palm and the thumb (37) (Figure 3). DNA pol λ 
 13 
is a template dependent DNA pol, but can perform template independent incorporation with 
low efficiency (38). Strand displacement activity is limited by the presence of a phosphate 
at the 5′ end of the gap by DNA pol λ. A high affinity for dNTPs by DNA pol λ, unlike 
DNA pol β, suggests a possible role in DNA repair when the intra-cellular dNTP 
concentrations are low (38). The dRP lyase activity of DNA pol λ is likely known to 
proceed via beta elimination using Lys310 as a major catalytic residue in short patch BER 
(39,40).  
 
 
 
 
 
 
Figure 3. Domain organization of DNA polymerase λ . The domain of DNA pol λ site: BRCT, Ser-Pro rich 
domain (S-P), 8 kDa domain and the polymerase catalytic domain composed of fingers, palm and thumb 
subdomains. The 39kDa domain is very homologous to DNA pol β. Reproduced from Garcia-Diaz, M. et. al., 
DNA Repair, 4, 1358-1367 (2005).  
 
 
 
Functional roles of DNA polymerase λ: 
 
DNA pol λ shares similar biochemical activity as DNA pol β including the dRP lyase 
activity, hence a role in BER was proposed (41,42). DNA pol λ is able to perform TLS in 
an error free manner over 2-hydroxy-adenine and a more often formed lesion produced by  
reactive oxygen species called 7,8-dihydroxoguanine (8-oxo-G) along with auxiliary 
proteins PCNA and RP-A (43). In a very recent study DNA pol λ along with MUTYH was 
shown to have a role in DNA repair of 8-oxo-G lesion (44). DNA pol λ also functions in 
non-homologous end joining (NHEJ). The BRCT domain of pol λ is important for 
interaction with proteins that function in NHEJ (45,46). DNA pol λ is also known to play a 
role in V(D)J recombination by joining of the heavy chain junctions in B-cells since mice 
deleted of DNA pol λ have shorter junctions (47).  
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Structural insight in DNA polymerase λ  
 
DNA Pol λ fills in short gaps when the 5′ end of the gap contains a 5′-phosphate. This 
phenomenon is explained by the presence of an 8kDa domain that is known to interact with 
the 5`-phosphate (48) (Figure 4).  
 
 
 
Figure 4: Subdomain organization of DNA polymerase λ . Ribbon representation of the 39kDa catalytic 
core of DNA pol λ in complex with a two-nucleotide gap (the DNA is shown in stick representation). The 
molecular surface is shown in transparent gray. The atomic coordinate corresponds to PBD IRZT. 
Reproduced from Garcia-Diaz, M. et. al., DNA Repair, 4, 1358-1367 (2005). 
 
 
Analyses of the X-ray crystal and computational studies of binary state (DNA pol λ 
complexed with DNA) and ternary state (DNA pol λ bound to the DNA and the correct 
incoming dNTP) complexes have shown that DNA pol λ undergoes a dNTP induced 
conformational change. It is known that the conformational change form a binary to the 
ternary state of DNA pol λ is minor in comparison to DNA pol β, another DNA pol from 
the same X family. DNA pol λ remains in a close subdomain conformation whether or not 
an incoming nucleotide is bound. Although, upon binding of the correct incoming 
nucleotide, the enzyme:DNA complex undergoes a transition form an inactive state  (closed 
state) to an active state (open state) (49-51). The active site amino acid residues help to 
coordinate the chemical reaction of the enzyme:DNA complex. These protein residues act 
as the steric gatekeepers regulating the assembly of the active site of the chemistry (52). 
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Tyr505 and Phe506 of DNA pol λ are important for nucleotide discrimination. Tyr505 
moves in order to permit entry of the dNTP into the active site of DNA pol λ (48,51). This 
movement allows for the repositioning of DNA templating base into the active site. Phe506 
blocks interaction between Arg258 and Asp192 in closed state allowing for DNA motion 
towards the closed conformation. IIe492 interacts with Asp192 and sterically inhibits the 
flipping of the Phe506 to a closed conformation. Arg517 is important for coupling of the 
DNA template movement to the binding of the correct dNTP in the closed state (50). 
Finally it has been shown that DNA pol λ is able to perform gap filling longer than 1nt 
during DNA repair and this was structurally explained by a mechanism called “scrunching” 
(53). 
 
 
Proliferating Cell Nuclear Antigen (PCNA)  
 
PCNA is a protein that is evolutionarily conserved and is found in all eukaryotic species 
from yeast to human as well as in archea and a member of the DNA sliding clamp proteins. 
In E.coli the DNA pol III β-subunit and in E.coli bacteriophage T4, the gene 45 protein 
regulate the processivity of the replicative DNA pols (54,55). PCNA is functionally 
associated with DNA replication, DNA repair, chromatin remodeling, cell cycle control and 
sister-chromatid cohesion.  
 
Structural insight: 
 
Alignment of amino acid sequences of PCNA from different species show considerable 
homology and evolutionary conservation. Surprisingly the yeast and human PCNA share 
only 35% sequence homology, but their three-dimensional structure is highly 
superimposable (56). The eukaryotic PCNA is composed of three identical monomers, 
linked in a head to tail fashion, forming a homotrimer and an overall toroidal shape. Each 
monomer consists of two similar domains linked by an interdomain connecting loop (57-
59). There are two PCNA-specific binding motifs identified, of which the PIP-box (PCNA-
interacting protein box) is the best studied so far (60,61). The consensus sequence of the 
PIP box is QXX (M/L/I) XX (F/Y)(F/Y). Another PCNA binding motif (KA 
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(A/L/I)(A/L/Q) XX (L/V) known as KA-box was identified which is distinct from the 
classical PIP-Box (62). Residues L121 to E132 at the interdomain connecting loop of 
PCNA was mapped to be the interacting sites for many proteins. This loop is recognized by 
several proteins like DNA pol δ, p21, flap-endonuclease 1 (FEN-1) and DNA ligase I (63-
66). Another protein interacting sequences is in the N-terminal region including the inner 
α-helices, which forms part of the binding site for cyclin D and the C-terminal tail, for the 
interaction with DNA pol ε, replication factor C (RF-C), CDK2 and GADD45 (67-69). 
 
 
Post-translational modifications of PCNA: 
  
PCNA is modified by different post-translational mechanism like ubiquitination, 
phosphorylation, acetylation, methylation and sumoylation. One of the well-documented 
PCNA posttranslational modifications is ubiqutination. Lysine residues at position 164 are 
the highly conserved and targeted for ubiquitination. Attachment of a single ubiquitin 
moiety leads to monoubiquitination and building up of ubiquitin chain through  Lys63 
results in polyubiquitination (70). Monoubiqutination occurs in a sequential manner, 
ubiquitin-activating enzyme E1 being the first, the ubiquitin-conjugating enzyme E2 (which 
in humans might be either Rad6A or Rad6B) and a RING finger containing E3 ubiquitin 
ligase called Rad18 (71,72). Polyubiquitin chain building requires the ubiquitin-conjugating 
enzyme Ubcl13-Mms2 and a specific RING-finger containing E3 ubiqutin ligase (73). In 
yeast it is Rad 5 and in humans SHPRH (SNF2 histone, linker PHD RING helicase), HTLF 
(helicase like transcription factor) and RNF8 (ring finger protein 8) (74-76). Lysine 164 of 
PCNA is also the target for another modification designated as sumoylation (70). It 
involves the attachment of a small protein called SUMO (small ubiquitin related modifier) 
observed in yeast. Lysine 127 is also a known target for sumoylation, lacking in higher 
eukaryotes. Sumoylation of yeast PCNA, is a trigger for recruitment of a specific DNA 
helicase (ySrs2), which blocks recombination events during replication (77).  
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Figure 5.Ubiqutination and sumoylation of PCNA: Ubiquitylation (U) or sumoylation (S) of PCNA leads 
to affinity changes for DNA pol and in the case of sumoylation, the recruitment of helicase Srs2. Reproduced 
from  Lopez de Saro, Current Genomics, 10, 206-215 (2009). 
 
 
Phosphorylation of Tyr21 in both humans and mouse cells stabilizes chromatin bound 
PCNA (78). Acetylation is another modification detected on PCNA. Acetylated and 
hyperacetalyted PCNA are found on the chromatin and localization of the non-acetylated 
form in the nucleosol, strongly suggest that PCNA translocation is dependent on the 
acetylating status (79). Methyl esterification of PCNA on glutamic acid and aspartic acid is 
a new modification and its functional consequence have yet to be unveiled in detail (80). 
 
 
Role of PCNA in DNA repair and translesion synthesis: 
 
PCNA is an indispensable part of several repair pathways such as mismatch repair (MMR), 
nucleotide excision repair (NER) and BER (54,55). PCNA interacts with MutS 
homologue1 (MSH3), MutS homologue (MSH6), exonuclease 1 (Exo1) and MutL 
homologue (MLH1), components of the MMR pathway (81,82). The endonuclease 
xeroderma pigmentosum complementation group G (XPG) known to play a role in NER 
pathway interacts with PCNA (83). DNA damage caused by oxidating, reducing or 
alkylating agents and misincorporated uracils is repaired by BER. PCNA is associated with 
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the recruitment of BER proteins to the site of action via long-patch BER. Its interacting 
patners are DNA glycosylase (uracil DNA glycosylase, UNG2), methylpurine-DNA 
glycosylase (MPG), NTHL1 (endonuclease III), human MutY homologue (hMYH), AP-
endonuclases, DNA pols δ, β and ε and X-ray repair complementing defective repair in 
Chinese-hamster cells (XRCC1) (reviewed in (84)). 
 
 
 
 
Figure 6.Translesion DNA synthesis and DNA polymerase switch. The example given demonstrates TLS 
and DNA pol switch after thymine dimers. Courtesy to Ursula Hübscher. 
 
 
In eukaryotic cells a crucial pathway for DNA damage tolerance is translesion synthesis 
(TLS). There are specific DNA pols that are able to carry out DNA synthesis past different 
lesions. Recent results have shown that the lesion bypass activites of several TLS DNA 
pols are increased by their physical interaction with PCNA. Since TLS requires the 
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interplay between the specialized DNA pols η, ι, κ, λ and the replicative DNA pol δ and ε 
(85). PCNA, with its different posttranslational modifications is an ideal candidate for 
coordinating their functions and recruiting them to the replication fork after the damage has 
occurred. The switch from a replicative DNA pol δ to TLS DNA pol η and ζ is determined 
by the monoubiqutination of PCNA (86) (Figure5). Figure 6 shows a model for TLS and 
the DNA pol switch after DNA damage. 
 
Replication protein A (RP-A)  
 
RP-A is a human single strand DNA (ssDNA) binding protein (87). ssDNA is an 
intermediate of DNA metabolism which has to be protected from unwanted attack by 
endonucleases and genotoxic agents (88). RP-A is localized in the nucleus and is present in 
the replication foci in human cells (89-91).  
 
 
Structure of RP-A and binding mode to single-stranded DNA: 
 
In eukaryotes RP-A is a heterotrimer composed of three tightly associated subunits of 70, 
32 and 14 kDa (refered to as RPA-70, RPA-32 and RPA-14, respectively). RP-A binds 
ssDNA in a highly sequential manner with a 5` to 3` binding polarity (92-94). The 
oligosaccharide / oligonucleotides binding fold (OB-fold) is the central structural and 
functional element of RP-A. RP-A is known to contains six OB folds, each of which 
consists of five β-strands arranged in a β-barrel shape. The RP-A 70 subunit contains four 
OB-folds designated as DNA binding domain A (DBD-A), DBD-B, DBD-C, and DBD-F. 
RP-A 32 subunit contains DBD-D and RP-A 14 has DBD-E. DBD-A and DBD-B of RP-A 
70 is the major ss DNA binding domain. DBD-A and DBD-B initiate the binding 
interaction with a length of 8-10 nucleotides at the 5`-side of ssDNA. The binding of 13-22 
nucleotide occurs with the additional involvement of DBD-C. Hence a cooperative binding 
of all four RP-A DBD (A-D) requires approx 30nt of ssDNA (95,96). In addition to the 
above-mentioned domain RP-A 32 also contains an unsaturated N-terminal 
phosphorylation domain. RP-A is known to be phosphorylated in a cell cycle dependent 
manner. RP-A undergoes phosphorylation during G1/S transition and in the M-phase 
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(97,98). Thus the functional role of RP-A hyperphosphorylation might be to shift a fraction 
of the cellular pool of RP-A from replication to DNA repair (99). 
 
Interaction of RP-A with DNA repair proteins: 
 
RP-A is required for all major repair pathways namely NER, BER, MMR and DNA 
double-strand break repair (DSBR) and homologous recombination (HR). In NER RP-A is 
involved in recruiting XPG, XPA and ERCCI-XPF endonuclease (100-102). RP-A 
participates in the gap filling reaction along with PCNA and DNA pol δ and ε. RP-A was 
implicated in BER via interaction with human uracil-DNA glycosylase (UNG2) and its 
stimulatory effect on long-patch BER. RP-A is also involved in MMR repair. RP-A has 
also been shown to interact with RAD52 and RAD51 proteins in the homologous 
recombination pathway (103). Human RP-A can also interact with the breast cancer 
susceptibility proteins BRCA1 and BRCA2 as well as tumor suppressor p53 protein 
(104,105).  
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Abstract 
 
DNA polymerase λ (pol) a member of the DNA polymerase X family has a role in non-
homologous end joining and is believed to play an important role as an accurate translesion 
DNA pol in base excision repair after DNA replication. We show here that a hydrophobic 
substitution mutant of the highly conserved residue at the active site of human DNA pol λ 
(Y505M) allows better incorporation of the correct nucleotide (dCTP) over an O-6-
methylguanine (O-6-mG) template relative to the non-complementary nucleotide (dTTP) 
usually incorporated by a variety of DNA pols. In contrast the wild-type DNA pol λ 
incorporated as expected preferentially the incorrect dTTP. This is the first report of a DNA 
pol showing faithful bypass of the O-6-mG lesion and can help to elucidate the molecular 
basis for the mutagenic potential of this lesion. When, however, RP-A was included in the 
reaction on the O-6-mG lesion inhibition of dCTP and dTTP incorporation was seen for 
both the wildtype and the Y505M mutant DNA pol λ suggesting a modulatory role of this 
auxiliary protein over this lesion.  
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Introduction 
 
There is substantial evidence that genetic instability is displayed with increased rate of 
errors in DNA synthesis. In this process, nucleotide selection within the active site of a 
DNA polymerase (pol) is the major contribution to the fidelity of DNA synthesis (1). 
Nevertheless, numerous endogenous and exogenous agents damage DNA. Some of the 
damage may escape repair and compromise the fidelity of replication and transcription (2). 
One such DNA lesion is O-6-mG, caused by exogenous methylating agents like N-methyl-
N-nitrosourea, methyl methane sulfonate, N-methyl-N′-nitro-N-nitrosoguanidine and 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone produced by tobacco burning and 
endogenous products of metabolism like betaine and choline, along with chemotherapeutic 
agents procarbazine and temazolomide (3-5). Methylating agents primarily react with 
exocyclic nitrogen or oxygen atoms by adding a methyl group on purines and pyrimidines, 
resulting in an impaired adduct, O-6-mG (2). The adduct O-6-mG mispairs with an 
incorrect thymine during DNA replication instead of a correct cytosine, resulting in 
GC→AT transition mutation (6). A ubiquitous O-6-methylguanine-DNA-methyltransferase 
(MGMT) in a stoichiometric fashion repairs O-6-mG by directly reverting DNA base 
damage (7). MGMT transfers the methyl group from the mutagenic DNA lesion to a 
cysteine residue with in the active site, rendering it incapable of continued repair, hence the 
number of lesion that can the cleared from a cells genome is limited by the available 
MGMT molecules, unless more of the protein is made (8). This type of repair is error free 
and noncytotoxic.  However, in many human solid tumor cell lines and in some non-tumor 
tissues the ability to repair O-6-mG is lacking due to the inactivation of MGMT (9). The 
initial event in O-6-mG induced mismatch repair may be the recognition of dT-O-6-mG 
(after removal of methyl group by MGMT) by the hMSH2. Functional deficiency of these 
mismatch recognition proteins imparts resistance to alkylation-induced cytotoxicity 
(10,11). Alternatively, a G:T specific thymine DNA glycosylase can also remove thymine 
from dT-O-6-mG base pair, allowing for the abasic site to be acted upon by 
apurinic/apyrimidinic (AP) endonucleases. However, it was shown that DNA pol β along 
with G:T-specific thymine-DNA glycosylase (along with other proteins such as MutSα) 
may be involved in the futile cycling at the O-6-mG lesions (9). 
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It has been shown that O-6-mG lesion blocked E.coli DNA pol I Klenow fragment as well 
as the eukaryotic DNA pol α involved in DNA replication (9,12). The translesion synthesis 
(TLS) Y family DNA pols η and κ show similar efficiencies for insertion of dCTP and 
dTTP opposite the O-6-mG, while DNA pol ι, which had a strong preference for dTTP, 
along with the major repair enzyme DNA pol β (13,14). Another report suggested that 
DNA pol κ is a poor, TLS DNA pol over O-6-mG, but when it incorporated either T or C 
efficient elongation is achieved by the replicative DNA pol δ (15). The above studies 
indicated that all known DNA pols incorporate the incorrect thymine at equal or higher 
frequency than the correct cytosine opposite O-6-mG. DNA pol λ was shown to incorporate 
dTTP at relatively high efficiency then dCTP for TLS past O-6-mG (16). Recently we have 
shown that pol λ is very efficient in performing error-free TLS past an 8-oxo-G and 2-OH-
A lesions along with auxiliary proteins PCNA and RP-A (17,18).  
 
In order to understand the carcinogenic mechanism of O-6-mG we studied the behaviour of 
DNA pol λ in the presence of the auxiliary proteins RP-A and PCNA. We furthermore 
constructed and characterized the biochemical properties of DNA pol λ wt by exchanging 
the conserved Y505 amino acid of the nucleotide-binding domain with hydrophobic amino 
acid residue methionine in the presence of auxiliary proteins RP-A and PCNA. DNA Pol λ 
conserved active site residue Y505 was shown to be involved in determining nucleotide 
selectivity opposite the lesion (19-21). Work of the group of Marx et al suggesting that 
hydrophobic substitution mutations can result in a more selective enzyme (22,23). Our data 
suggests that Y505M mutant is a novel in-vitro evolved DNA pol λ that allows the error 
free TLS over O-6-mG by incorporating the correct dCTP. This is in contrast to the 
parental pol λ wt, as expected, incorporated the wrong nucleotide dTTP. Finally, the 
auxiliary protein RP-A displays a curial role in negatively regulating the TLS of both pol λ 
wt and Y505M over O-6-mG.  
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Materials and Methods 
 
 
Oligonucleotide synthesis 
 
Oligonucleotides were synthesized by Purimex. All oligonucleotides were purified by 
denaturing polyacrylamide gels (PAGE). 
 
Enzymes and Proteins 
 
The bacterial expression plasmid pRSET-B encoding human DNA pol λ wt and the 
Tyr505Ala were cloned, expressed and purified as described previously (24). Tyr505Meth 
was cloned and purified as described previously, Wimmer et al (25). Recombinant human 
PCNA and human RP-A were express and purified as described, Maga et al (17).  After 
purification, the proteins were >90% homogenous as judged by SDS-PAGE and Coomassie 
staining. 
 
 
Single nucleotide insertion assays 
 
The primer/template complexes (whose sequence as indicated in the respective Figure) 
were annealed as described in the primer extension assay. The reactions were initiated by 
adding 10µM of the indicated dNTP (unless indicated in the figures), in a reaction mixture 
(10µl) containing 50mM Tris-HCl pH 7.0, 0.25mg/ml BSA, 10mM DTT and 10fmol of the 
5′32P-labelled primer template, DNA pol λ wt, Y505M, and Y505A at 40nM and 1.0mM 
Mg2+, and incubated at 37oC for 15min. After incubation, reactions were stopped by adding 
loading buffer (95% formamide, 10mM EDTA, Xylene cyanol and Bromophenol blue) 
heated at 95oC for 3min, loaded and separated on a 7M Urea 15% polyacrylamide gel and 
the products mixture analysed by autoradiography. 
 
 
Sequence dependent incorporation assay 
 
The primer/template complexes were annealed as described in the primer extension assays 
(sequence as depicted in the respective Figure). In order to determine the rates of dCTP and 
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dTTP incorporation with respect to nucleotide substitution after the lesion, dCTP and dTTP 
were titrated from 1 to 100µM in reaction conditions as stated above in the primer 
extension assay. The observed rates of nucleotide incorporation were calculated from the 
values of integrated gel band intensities. 
 I*T/IT-1 
Where T is the target site, the template position of interest; I*T is the sum of the integrated 
intensities at positions T, T + 1,……, T + n 
All the intensity values were normalized to the total intensity of the corresponding lane to 
correct for difference in gel loading. The apparent Km and kcat values were calculated by 
plotting the initial velocities in dependence of the nucleotide concentration [dCTP] and 
[dTTP], and fitting the data according to the Michaelis –Menten equation: 
Kcat [E]o/(I+km/[dNTP]) 
Where [E]0, was the input enzyme concentrations. Nucleotide concentrations used were 
1µM, 10µM and 100µM. Nucleotide incorporation efficiencies were defined as the kcat/Km 
ratio. Under single nucleotide incorporation conditions kcat=kpolkoff/(kpol+koff) and 
Km=Kskoff/(kpol+koff), where kpol is the true polymerization rate, koff is the constant for 
nucleotide binding. Thus, kcat/Km values are equal to kpol/Ks.  
 
 
Results 
 
 
The error-prone bypass of O-6-mG by wild-type DNA polymerase λ is negatively regulated 
by RP-A. 
 
DNA pol λ wt was first were analysed on 39:72 template, containing a single O-6-mG 
lesion, in the presence of the indicated dNTP. DNA pol λ wt incorporated the “correct” 
nucleotide”  (dCTP) opposite normal G in contrast allowing for “incorrect nucleotide” 
(dTTP) incorporation opposite O-6-mG compared to the dCTP insertion (Fig 1a lane 3 and 
Fig 1b lanes 3 and 5). We have previously shown that the auxiliary proteins PCNA and RP-
A are able to increase the catalytic efficiency, fidelity and TLS of DNA pol λ over 8-oxo-G 
and 2-OH-A. As shown in Fig 1c (lanes 1-4, 6-9) increasing concentrations of RP-A alone 
was able to inhibit dCTP and dTTP incorporation opposite the O-6-mG by DNA pol λ wt 
 26 
in a concentration dependent manner. However dCTP incorporation by DNA pol λ wt was 
reduced by 79% and the dTTP incorporation was reduced by 66% by RP-A. PCNA showed 
no effect on dCTP and dTTP incorporation opposite O-6-mG (Fig 1d, lanes 1-4 and lanes 
6-9). These data demonstrate that RP-A has a curial role in negatively regulating the error 
prone TLS by DNA pol λ wt across O-6mG. 
 
 
Single base substitution of DNA polymerase Y505M allows a reduced DNA polymerization. 
 
We have previously shown that a highly conserved (Fig 2a) DNA pol λ residue Tyr505 is 
important for nucleotide discrimination, being involved in interactions with the incoming 
dNTP. We therefore tested the mutant Y505M and the wt for DNA polymerase activity a 5` 
-end-labelled 39:72 primer/template DNA oligonucleotide substrate. All the reactions were 
performed in the presence of Mg2+ and the products were resolved by sequencing gel 
analysis. As shown in (Fig 2b) the Y505M mutant displayed a reduced activity (lanes 7-10) 
compared to the DNA pol λ wt (lanes 2-5). The kinetic parameters for nucleotide 
incorporation for both the enzymes were determined as shown in (Fig 2c). However, 
Y505M substitution showed an approx two-fold decrease in the km for the nucleotide 
substrate with respect to DNA pol λ wt. As a result, the Y505M mutant displayed a two-
fold reduction in the nucleotide utilization efficiency (kcat/Km). 
 
 
The mutant DNA polymerase λ Y505M but not the wildtype can incorporate the correct 
dCTP opposite a O-6-mG in a single nucleotide insertion experiment 
 
Both wt and Y505M DNA pol λ were next analysed on 39:72 template, but containing a 
single O-6-mG lesion, in the presence of the indicated dNTP. Y505M incorporated the 
“correct” (dCTP) opposite O-6-mG when compared to the dCTP insertion by pol λ wt (Fig 
3a, compare lanes 3 and 8). On the opposite the mutant Y505M catalysed “incorrect” dTTP 
insertion opposite O-6-mG at a highly reduced rate compared to the DNA pol λ wt (lanes 5 
and 10). In comparison, no difference was noticed against undamaged dG for both DNA 
pol λ wt and Y505M (Fig 3b lanes 3, 8). Interesting Y505M showed poor TLS over O-6-
mG in the presence of all four nucleotide in comparison to wt (Fig 3a, compare lanes 6 and 
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11). In order to further investigate these effects, dNTPs titrations were performed in the 
presence of an enzyme concentration and the data was fitted to Michaelis-Menten equation. 
As shown in (Fig 3c) the DNA pol λ wt incorporates dTTP opposite O-6-mG almost 3-fold 
better than dCTP, while Y505M did not incorporate any “incorrect” dTTP opposite the 
lesion. Moreover, Y505M incorporated the “correct” dCTP opposite the lesion almost 9-
fold better than the wt. The kinetic parameters are summarised in Table 1. Neither wt nor 
Y505M showed any difference in misincorporation of dTTP opposite dG (Fig 3d), 
suggesting that Y505M does not induce any increase in discrimination against a normal 
T:G mismatch. However on substituting Y505 with the non-hydrophobic amino acid 
alanine incorporated the dTTP more preferentially than the correct dCTP (Fig 3e, compare 
lane 3 and 5). 
 
 
The Y505M DNA polymerase λ mutant did not have an intrinsic preference for the 
incorporation of dCTP 
 
When both the wt and Y505M DNA pols were tested in the presence of 8-oxo-G lesion, 
they both incorporated dCTP better than dATP opposite the lesion, without differences 
between them, suggesting that the observed effect for the mutant Y505M was specific for 
dCTP incorporation against O-6-mG (Fig 4a compare lanes 3 and 8). Similarly, when tested 
on an 8-oxo-A template, both enzymes showed preferential incorporation of dGTP without 
any difference between wt and Y505M (Fig 4b compare lanes 4 and 9). These two control 
experiments suggested that the Y505M mutant did not have an intrinsic preference for the 
incorporation of dCTP.  
 
 
The Y505M DNA polymerase λ favours dCTP incorporation opposite O-6-mG 
independently from the sequence context.  
 
To test for the effect of flanking nucleotides on O-6-mG, we next titrated dCTP and dTTP 
on primer/template where the first nucleotides in the template strand was O-6-mG, 
followed by either G, A, T or C respectively. No significant difference was observed, with 
respect to dCTP or dTTP incorporation, on O-6-mG/C and O-6-mG/T templates (Figure 
S1A). With the O-6-mG/G template, it was seen that the Y505M mutant was more efficient 
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than wt in incorporating dCTP (Fig 5a) and less efficient in incorporating dTTP (Fig 5c). 
Similarly, with the template O-6-mG/A the wt was more efficient than Y505M in 
incorporating dTTP (Fig 3b) but less efficient in incorporating dCTP (Fig 5d). As expected 
most product accumulated at position +2 (Fig 5a and b). However significant accumulation 
of +3/4 products could be seen with the O-6-mG/G template and dCTP as substrate (Fig 
5a), whereas only very few +3 products were generated with the O-6-mG/A template in 
combination with dTTP (Fig 5b). This indicated that in the presence of dCTP, DNA pol λ 
makes template slippage at the C, at +3 position, thus the +3/4 products are generated by 
using the GG at position 4 and 5 as the templating bases. This explains the fact that only a 
minimal amount of +3 products are detected with 6-mG/A templates in combination with 
dTTP, since in such case no slippage can occur.  
 
The error-free bypass of O-6-mG by DNA polymerase λ Y505M is also negatively 
regulated by RP-A. 
 
The data so far indicated that Y505M was able to perform error-free incorporation of dCTP 
opposite O-6-mG more efficiently than the wt, at an expense of reduced translesion 
synthesis. Thus, finally the PCNA and RP-A effects on O-6mG bypass by Y505M was 
investigated. As shown in Fig 6a (lanes 1-4, 6-9) increasing concentration of RP-A alone 
was also able to inhibit dCTP and dTTP incorporation opposite the O-6-mG by Y505M in a 
concentration dependent manner. Lanes 0 and 5 are control reactions in the absence of 
dNTPs.   However the “correct” dCTP incorporation by Y505M was reduced by 53% under 
the same condition as DNA pol λ wt displaying the fact the Y505M still allows for error-
free incorporation opposite O-6-mG under such conditions. The  “wrong” dTTP 
incorporation was reduced by 80% by Y505M respectively (Fig 6b). When tested PCNA 
showed no effect on dCTP and dTTP incorporation opposite O-6-mG (Fig 6c lanes). These 
data suggest that RP-A has a curial role in negatively regulating the TLS by pol λ wt and 
Y505M across O-6mG. 
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Discussion 
 
DNA encounters various assaults in the native structure and sequence throughout the life 
span of a cell. The common types of DNA damage like the O-6-mG damage that interferes 
with replication fork progression can cause cell-cycle arrest and cell death. Furthermore, 
DNA lesions that persist into the S phase of the cell cycle can obstruct replication fork 
progression, resulting in the formation of replication-associated DNA double-strand breaks 
(DSBs) (26). DSBs are generally considered to be the most toxic of all DNA lesion. The 
fact that all known DNA pols to date show a preferential incorporation of T opposite O-6-
mG, led us to investigate the molecular mechanisms for nucleotide selection by DNA pol λ 
opposite this particular lesion along with auxiliary proteins. RP-A is an important “sensor” 
protein for DNA replication fork stalling and was shown to act as a molecular switch to 
activate DNA pol λ dependent highly efficient and faithful repair of 8-oxo-G, repressing 
DNA pol β activity along with PCNA (27).RP-A inhibited the dCTP and dTTP 
incorporation by DNA pol λ wt, suggesting that RP-A effect is influenced by DNA 
template containing lesion. PCNA, which is known to interact both functionally and 
physically with DNA pol λ showed no effect over this lesion .The above finding is in 
contrast to the recent data from our laboratories suggesting that DNA pol λ was most 
accurate in dealing with 8-oxo-G and 2-OH-A in combination with PCNA and RP-A. This 
allows for strong evidence that RP-A and PCNA plays a vital role in oxidative repair and 
also allows for MGMT or mismatch repair (MMR) proteins to take over O-6-mG. However 
the hydrophobic substitution mutation of the active site residue Y505 presented in this 
study is believed to be involved in dNTP binding completely changed nucleotide 
incorporation selectivity opposite the O-6-mG lesion by preferentially incorporating the 
correct nucleotide dCTP. This novel phenomenon was not shared by non-hydrophobic 
mutation Y505 to alanine and other DNA pols belonging to the X family, which produced 
high error rates when replicating over the O-6-mG lesion. Our data also shows that the 
preferential incorporation of dCTP opposite O-6-mG by Y505, is specific for this lesion, 
since no differences in incorporation opposite 8-oxo-G or 8-oxo-A between the Y505M 
mutant and the wt enzyme could be seen. Pol λ wt and Y505M misincorporation frequency 
of deoxynucleotide triphosphate opposite O-6-mG are not influenced by each possible 
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nearest-neighbour context, contrasts with in vitro primer extension studies showing that 
misincorporation by other pols is dependent on the surrounding sequence (28). With 
reference to the extension step, when starting from an O-6-mG primer basepair, most 
eukaryotic pols combine relative high discrimination and low efficiency. In agreement to 
the published data by Blanco et al, Y505M   represent a similar pattern as DNA pol λ, 
having a relativity high discrimination and relatively lower extension efficiency for the 
mutagenic pair O-6-mG/dT than the correct base pair O-6-mG/dC, allowing us to conclude 
that the in-vitro generated Y505 would be a best candidate to guarantee an error free 
extension step during by pass of O-6-mG (Figure S2A).  
 
 
 
Conclusion 
 
In the present study we show the RP-A, an essential component of the cellular DNA 
replication and DNA repair machineries could not only modulate the intrinsic miscoding 
ability of DNA pol λ but can also completely suppress the incorporation of nucleotides 
opposite O-6-mG in a concentration dependent manner. The hydrophobic substitution 
mutant of the highly conserved residue Y505 in the active site of DNA pol is essential for 
its fidelity. The Y505M mutant of the pol λ is the first DNA pol described to date, which is 
able to preferentially incorporate dCTP opposite O-6-mG. 
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Figure Legend  
 
Figure 1. RP-A inhibits the bypass of O-6.mG lesion by DNA polymerase λ.  
Experiments were performed as described in Materials and Methods. The template 
sequence is indicated on top of each panel (A) Single nucleotide incorporation opposite 
control template by DNA pol λ wt (lanes 2-5). Lane 1: control in the absence of dNTP and 
lane 6 in the presence of all four dNTPs. (B) As in panel A but opposite O-6mG template. 
(C) Incorporation opposite O-6.mG by 40nM of DNA pol λ wt of dCTP (lanes 1-4) and 
dTTP (lanes 6-9) in the absence of (lanes 1 and 6) or in the presence of (lanes 2-4, 7-19) of 
different amounts of RP-A. Lane 0 and 5 are controls in the absence of dNTPs. (D) Effect 
of increasing amounts of RP-A on the incorporation of dCTP and dTTP opposite O-6-mG 
by DNA pol λ wt. (E) As in panel C but in the presence of increasing amounts of PCNA. 
 
 
Figure 2. DNA synthesis activity by DNA polymerase λ wt and Y505M.  
(A) The sequence of human pol λ has been aligned to human pol β, µ and TdT. The 
tyrosine residue considered in this study is highlighted in the rectangular box and the 
respective substitution made by site-directed mutagenesis is indicated on the top. 
Conserved residues are indicated in bold. Multiple sequence alignment of the conserved 
Tyrosine residue in DNA pol λ from human, monkey, dog, cattle, rat, mouse, chicken, frog 
and zebra fish are shown on the left side. The conserved tyrosine residue is highlighted in 
the rectangular box and the conserved residues are indicated in bold. (B) The sequence of 
the template strand is indicated on top of each panel.  Primer extension assays were 
performed as described in Materials and Methods section the presence of 5′ labeled 39/72-
mer template. Titration of DNA pol λ wt (lanes 2-5), Y505M (lanes 7-10) in the presence 
of 10µM dNTPs. Lanes 1and 6: control reactions in the absence of nucleotides. (C) 
Variation in the initial velocities of the reaction catalyzed by 40nM DNA pol λ wt and 
Y505M on the undamaged template in the presence of dNTP as a function of the nucleotide 
substrate. Values are the mean of two independent experiments. Error bars are ± SD. 
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Figure 3. Translesion synthesis by DNA polymerase λ wt and Y505M. 
The sequences are as indicated on the top of each panel. The experiments were carried out 
as indicated in Materials and Methods. (A) Single nucleotide incorporation opposite O-
6mG damaged template by DNA pol λ wt (lanes 2-5) and Y505M (lanes 7-10) or pol β 
(lanes 12-15). Lane 1 is control reaction in the absence of dNTPs and lanes 6 and 11 in the 
presence of all dNTPs. (B) As in panel A, but in the presence of undamaged dG. (C) 
Variation in the initial velocities of the reaction catalyzed by 40nM DNA pol λ wt and 
Y505M as a function of the nucleotide substrate concentration. Values are the mean of two 
independent experiments. Error bars are ± SD (D) Incorporation of dTTP opposite dG by 
human DNA pol λ wt (lanes 2-4) and Y505M (lanes 6-8) at the indicated concentration. 
Lanes 1 and 5 are control reactions in the absence of dTTP. (E) Single nucleotide 
incorporation opposite the O-6mG lesion template by Y505A. 
 
 
Figure 4.TLS by pol λ wt and Y505M over 8-oxo-G and 8-oxo-A. 
Experiments were performed as described in materials and methods. The template sequence 
is as indicated on top of each panel. (A) Single nucleotide incorporation opposite 8-oxo-G 
by pol λ wt (lanes 2-5) and Y505M (lanes 7-10). Lanes 6 and 11 are in the presence of all 
four dNTP’s. (B) Incorporation opposite 8-oxo-A. As in panel A. Lane 1 control reaction in 
the absence of dNTP’s. 
 
 
Figure 5. The fidelity of 6-O-mG bypass by DNA polymerase λ wt and Y505M is not 
influenced by the sequence context.  
Experiments were performed as described in Materials and Methods. The template 
sequences are indicated on top of each panel. (A) Relative dCTP incorporation opposite the 
indicated template by DNA pol λ wt and Y505M at 0.1 µM and 1 µM. The product length 
is indicated on the bottom axis. (B) Relative dTTP incorporation opposite the indicated 
template by DNA pol λ wt and Y505M at 1µM and 10µM. The product length is indicated 
on the bottom axis. (C) Relative dTTP incorporation opposite the template indicated by pol 
λ wt and Y505M at 0.1 µM and 1 µM (D) Relative dTTP incorporation opposite the 
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indicated template by DNA pol λ wt and Y505M at 1µM and 10µM. All the values were 
obtained from 3 independent experiments. Error bars are ± SD.  
 
 
Figure 6. RP-A inhibits the error free bypass of O-6-mG lesion by DNA polymerase λ. 
Experiments were performed as described in Materials and Methods. The template 
sequence is indicated on top of each panel. (A) Incorporation opposite O-6.mG by 40nM of 
DNA pol λ Y505M of dCTP (lanes 1-4) and dTTP (lanes 6-9) in the absence of (lanes 1 
and 6) or in the presence of (lanes 2-4, 7-19) of different amounts of RP-A. Lane 0 and 5 
are controls in the absence of dNTPs. (B) Effect of increasing amounts of RP-A on the 
incorporation of dCTP and dTTP opposite O-6-mG by DNA pol λ wt. (C) As in panel A 
 but in the presence of increasing amounts of PCNA. 
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Table 1: Steady state kinetic parameters for nucleotide incorporation on the 
undamaged template by wt DNA polymerase λ and the Tyr505Met mutant1 
 
 
dNTP DNA pol λ  Km (µM) Kcat (min-1) Kcat/Km (µM-1min-1) 
wt 0.2122 0.023 0.108 
Tyr505Met 0.1409 0.0061 0.043 
1(Kcat/Km) stands for the catalytic efficiency displayed by DNA pol λ wt and the mutant 
Tyr505Met for the insertion of dNTP. 
 
 
 
 
Table 2: Steady state kinetic parameters for nucleotide incorporation on the O-6-mG 
template by DNA polymerase λ  wt and the Tyr505Met mutant1 
 
 
dCTP dTTP 
DNA pol λ  Km  
(µM) 
Kcat  
(min-1) 
Kcat/Km 
(µM-1min-1) 
Km  
(µM) 
Kcat  
(min-1) 
Kcat/Km 
(µM-1min-1) 
wt 0.18 0.013 0.07 0.04 0.008 0.2 
Tyr505Met 0.024 0.015 0.624 n.d. 2 n.d. 2 n.d. 2 
1(Kcat/Km) stands for catalytic activity displayed by DNA pol λ wt and the mutant 
Tyr505Met for the insertion of the indicated nucleotide.  
2n.d. non detectable incorporation of dTTP 
 
 
 
Supplementary: 
 
Figure S1A. The fidelity of 6-O-mG bypass by DNA polymerase λ wt and Y505M is not 
influenced by the sequence context. 
Experiments were performed as described in Materials and methods. The template 
sequence are indicated on top of each panel. (A) Relative dCTP (lanes 2-4) and dTTP  
(lanes 6-8) incorporation opposite O-6-mG by DNA pol λ wt. dCTP (lanes 10-12) and 
dTTP (lanes14-16) incorporation opposite O-6-mG by Y505M. Lanes 1,5,9,13 are control 
reactions in the absence of dNTPs. (B) Relative dCTP (lanes 18-20) and dTTP (lanes 22-
24) incorporation opposite O-6-mG by DNA pol λ wt. dCTP (lanes 26-28) and dTTP (lanes 
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30-32) incorporation opposite O-6-mG by Y505M. Lanes 17.21,25 and 29 are control 
reactions in the absence of dNTP′s. 
 
Figure S2A. Extension of mismatched primers containing O-6-mG lesion by DNA 
polymerase λ wt and Y505M. 
Experiments were performed as described in Materials and methods. The template 
sequences are indicated on top of each panel. (A) O-6-mG:C template – dCTP 
incorporation by DNA pol  λ wt (lanes 6-8)  and Y505M (lanes 2–4). Lanes 1 and 5 are 
control reactions in the absence of dCTP. (B) O-6-mG:T template – dCTP incorporation by 
DNA pol λ wt (lanes 14-16) and Y505M (lanes 10-12). Lanes 9 and 13 are control 
reactions in the absence of dCTP.  
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AIM 
 
 
Theories postulate that aging is triggered by cellular accumulation of oxidative DNA 
damage. Although more than 20 base lesions have been identified, 8-oxo-G is of special 
interest since it forms the high level of oxidative stress leading to mutations and eventually 
to cancer. DNA polymerase λ a member of the X family allows for the repair of this lesion 
via the BER pathway. The Werner syndrome protein (WRN), a member of the RecQ family 
of helicases, associates with BER proteins. The aim of the second part of the project was to 
understand a possible functional interplay of DNA polymerase λ and WRN in repair of 
oxidative damage.  
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INTRODUCTION 
 
 
RecQ helicases 
 
RecQ Helicases are one of the major proteins that are involved in maintaining genomic 
stability. RecQ proteins are highly conserved DNA helicases involved in DNA metabolic 
processes like DNA recombination, replication, and repair. Five different RecQ helicases 
have been identified in mammals, including humans. In contrast in Escherichia coli, 
Saccharomyces cerevisiae, and Schizosaccharomyces pombe, only one RecQ helicase has 
been identified. Human RecQ helicase are named RECQ1, Bloom  (BLM), Werner (WRN), 
RECQL4 and RECQL5 (133). 
 
Genetic Disorder of RecQ helicase 
 
Human RecQ helicases results in rare genetic disorders that lead to aging and cancer 
instability. The Werner syndrome (WS) and Bloom syndrome (BS) are associated with 
slow growth, abnormal facial features, infertility, and high onset of age-related diseases. 
WS patients are susceptible to early onset of sarcomas and mesenchymal tumors. BS 
patients have an early onset towards cancer. Individuals with mutation in the RecQ4 are 
prone to the Rothmund-Thomson syndrome (RTS). Pateins with RTS display growth 
deficiency, photosensitivity with poikilodermatous skin change, early graying and hair loss, 
jvenile cataracts and oesteogenic sarcomas. This leads to the RAPADILINO or the 
BALLER-Gerold syndrome. Genetic disorders associated with RecQ1 and RecQ5 
mutations, have not been identified so far (134,135).  
 
 
Properties of the WRN protein 
 
The WRN gene encodes a protein of 1432 amino acids with a molecular weight of 
163kDa.WRN contains a 3′→ 5′ exonuclease domain, an acidic region, a 3′→ 5′ helicase 
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domain, a RecQ C-terminal (RQC) domain, a helicase domain, a ribonuclease D C-terminal 
domain (HRDC) and finally a nuclear localization domain (136,137) (Figure 9).  
 
 
 
Figure 9. Domain organization of the WRN protein. A RQC, RecQ conserved C-terminal domain; HRDC, 
helicase and RNase D, C-terminal domain; NLS, nuclear localization signal. Reproduced from Bohr.V.A. 
Experimental Gerontology, 42, 876-878 (2007). 
 
 
WRN is a DNA structure specific helicase (138,139). The DNA G-quadruplex and triple 
helix are most preferred along with recombination intermediates like D-loops, holiday 
junction and three way junctions along with DNA replication structure like bubbles, forks 
and flaps (140-142). Single substitution mutation at K577M lacks ATPase activity and also 
the helicase activity. Unlike other RecQ helicase WRN processes a unique 3′→ 
5′exonuclease activity in the N-terminal region, mutation at residue E84A inactivates the 
exonuclease activity of WRN (143). The exonuclease can preferentially digest dsDNA with 
a 5′ over-hang, and substrates with blunt-ended dsDNA such as replication fork like 
structures, holiday junctions, or D-loops (144,145). The WRN exonuclease activity is 
coordinated in a Zn2+ dependent manner (146). The human WRN protein is concentrated in 
the nucleolus,this is in contrast to the mouse WRN which is localized in the nucleoplasm 
(147). WRN depleted primary fibroblast show retarded S and/or G2/M progression (148). 
WRN cells are selectively sensitive to the DNA damaging agents 4-nitroquiniline 1-oxide, 
camptothecin, hydroxy urea and are mildly sensitive to γ irradiation induced DSBs. 
Therefore it plays a role in DNA repair (149,150). Oxidative DNA lesions are known to 
accumulate in the H2O2 treated diploid WS fibroblasts (151). 
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Post-translational modifications of the WRN protein  
 
WRN is phosphorylated at serines, threonines, and tyrosines residues when cells are 
exposed to bleomycin and other replicative stress (152,153). Phosphorylation of Werner is 
dependent on the ataxia telangiectasia mutant protein (ATM) and the DNA PKc complex. 
C-Abl, a tyrosine protein kinase is also known to phosphorylate WRN (153). WRN is 
furthermore sumoylated in vitro and in vivo, though the functional consequence is yet to be 
understood (154). In addition to sumoylation, acetylation and tyrosine phosphorylation of 
WRN in nuclear trafficking (133). Acetylation of WRN by the transcriptional co-activator 
p300 is likely important in translocation of WRN from the nucleolus to nuclear foci 
(155,156). 
 
 
Figure 10. WRN posttranslational modifications. Post translational modification of WRN include: 
Phosphorylation on Ser/Thr or Tyr, sumoylation, acetylation and oxidation. The mediators and modifiers of 
WRN post-translational modifications are indicated. Functional effects of posttranslational modification are 
indicated. Two arrows indicate a stonger reaction than one arrow. Reproduced from Bohr.V.A, Trends in 
Biochem Sci, 33, 609-620 (2008).   
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The BER pathway 
 
Reactive oxygen species (ROS) are constantly generated in living organisms. The DNA 
bases are sensitive to oxidative DNA damage like the 8-oxo-G (157). The 8-oxo-G is a 
highly mutagenic miscoding lesion that can lead to G:C to T:A transversion mutations 
(158,159). There are two sub pathways of BER namely short patch (SP)-BER and long 
patch (LP)-BER. During SP-BER, only a few nucleotides are incorporated in the place of 
the damaged base; during LP-BER, two to six new nucleotides are incorporated. Specific 
DNA glycosylase, cleaves the N-glycosyl bond between the sugar and the base, releasing 
the damaged base to from an abasic site, termed apurinic/apyrimidinic site (160,161). There 
are several different glycosylase specific for certain lesions. DNA glysocylase are classified 
as mono- or bifunctional, depending on their reaction mechanisms. Monofunctional 
glycosylase (having only glysocylase activity) like UNG require another enzyme called the 
APE1 for the incision of the resulting abasic sugar residue leaving behind a 5′-deoxyribose 
phosphate (dRP). If the glycosylase is bifunctional having both glycosylase and AP-lyase 
activity such as OGG1 or NEIL1, then both base excision and an incision 3′ to the AP site 
occurs resulting in a one nucleotide gap that harbors a 3′-α, β-unsaturated aldehyde or 3′ 
phosphate. These one nucleotide gap requires the removal altered 3′-terminal groups prior 
to polymerization and/or ligation. The 3′-phosphoglycolate groups generated during direct 
SSBs can also be removed by APE-1 (162,163). After removal of the obstructive terminal 
or APE1 incision 5 to the AP site replacement of the excised nucleotide is performed by 
DNA pol β or DNA pol λ as a backup mechanism (164). This enzyme also removes the 
5′dRP group left behind by the APE1 incision. If the 5 terminals are refractory to this DNA 
pol β AP lyase activity, strand displacement synthesis is required for incorporation of 
multiple nucleotides. During LP-BER several enzymes like PCNA, FEN1, DNA pol β and 
DNA pol δ/ε coordinate to fix the lesion. The final step involves the sealing of the nick by 
either DNA Ligase I (LP-BER) or DNA Ligase III/ XRCC1 (SP-BER) (165). 
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Role of the WRN protein in BER 
 
 BER is involved in repairing oxidative DNA lesions like the 8-oxoG and 
formamidopyrimidines (166). Although WRN does not interact with human OGG1 its 
association with the DNA glycosylase NEIL 1, specific for repair of 8-oxo-G, is the early 
damage-sensing step of BER (167). Interaction between human apurinic/pyrimidinic 
(APE1) and WRN inhibits the WRN helicase activity preventing promiscuous unwinding 
(168). BLM and WRN interact with DNA pol β, stimulating the strand displacement 
activity and this is independent of the helicase activity of WRN and BLM (155,169,170). 
WRN efficiently stimulates FEN-1 cleavage, on a flap DNA structure, an intermediate 
generated during BER and branch-migrating double-flap substrates generating during 
replication (171). WRN deficiency leads to hyperactivation and rapid premature 
accumulation of protein carbonyls. High levels of oxidative stress and oxidative DNA 
damage correlates with increased risk of sarcomas (172). Although WRN is not considered 
to be directly involved in BER, an important role for WRN in BER is supported by the 
finding WRN-deficient cells accumulate 8-oxo-G (151). 
 
WRN interacting proteins for a variety of DNA transactions: 
 
WRN helicase interacts with several protein in DSBR. RAD51, a key player in the strand 
invasion event during HR, interact with WRN (173). RAD52 inhibits and enhances WRN 
helicase activity in a DNA structure dependent manner, whereas WRN increases the 
efficiency of RAD52-mediated strand annealing (174). RAD54, another key protein, co-
localizes with WRN in response to replicative stress (175). WRN also associates with the 
MRE11-RAD50-NBS1 complex via NBS1 and BRCA1 (176,177). BRCA1 stimulates the 
helicase activity of WRN. WRN is also known to participate in NHEJ since it interacts with 
Ku70-Ku80 heterodimer, a primary mediator of NHEJ and with DNA-dependent protein 
kinase (DNA PK) (152). WRN plays a role in MMR pathways, by removing mismatched 
nucleotide incorporation by a DNA pol during replication or DNA repair. WRN stimulates 
the extension activity of DNA pol δ and the family Y translesion DNA pols like η, ι and κ 
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over a lesion free and a lesion DNA template. It is also known that the WRN exonuclease 
fails to bypass certain DNA lesions like  8-oxo-G (145,178,179). WRN moreover interacts 
physically and functionally with several key proteins involved in replication, especially 
with RP-A, which stimulates the helicase activity (180,181). PCNA is also another key 
factor in replication interacting with WRN (180). Chromatin assembly factor-1 and WRN 
are both involved in the maintainance of genome stability (182). In response to DNA-
damaging signals, both these proteins relocate to sites where DNA synthesis occurs. The 
WRN syndrome protein is required for recruitment of chromatin assembly factor 1 
following DNA damage (182). Furthermore WRN deficiency is associated with defect in 
telomere maintenance. Studies show that WRN is associated with TRF1 and TRF2, both 
components of the shelterin complex (183). POT1 (protection of telomerase 1) is an 
ssDNA-binding protein that binds with high affinity to telomere repeats and strongly 
stimulates WRN helicase activity (183-185). The carboxyl-terminal part of WRN and the 
extreme carboxyl terminus of p53 can inturn be a region that plays an important role in 
regulating the functional state of p53. A cross talk between p53 and WRN helps preventing 
the accumulation of aberrations that give rise to premature senescence leading to cancer 
(186). WRN also interacts with exonuclease 1 (EXO-1) aviating the exonucleotytic and 
endonucleolytic incision function of EXO-1 (187). 
 
7,8-dihydro-8-oxo-guanine and DNA polymerase λ  
 
ROS (Reactive oxygen species) are generated by normal cellular metabolism and by 
exogenous agents. It is known that not all but most of the DNA lesions repaired by BER are 
products of ROS attack. There are up to 103 to 104 lesions generated per cell per day, the 
most common being, 8-oxo-G (188). 8-oxo-G is a highly mutagenic miscoding lesion that 
can lead to G:C to T:A transversion mutations. 8-oxo-G retains the ability to engage in 
correct Watson-crick base pairs with C, but oxidation of G (at C8) converts a hydrogen 
bond acceptor (N7) to a hydrogen bond donor, allowing a stable Hoogsteen base pair to 
form  between 8-oxo-G and A, which is not possible in undamaged DNA (189) (Figure 11).  
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Figure 11. Models of base pairing for 8-oxo-G a.) Oxidation of guanine at  C8 by reactive oxygen species 
(ROS). b.) 8-oxo-G in a Waton-Crick base pair with dC.dashed lines indicate potential hydrogen bonds. c.) 8-
oxo-G (syn) in a Hoogsteen base pair with dA (anti). Reproduced from Hsu.G.W, Nature, 431, 217-22(2004). 
 
 
The BER pathway is the primary mechanism for the repair of oxidative base damage, such 
as 8-oxo-G and formamidopyrimidine. BER has alternative pathways depending on the 
damage and the responsive enzymes. The presence of 8-oxo-G on the replicative strand can 
lead to frequent misincorporation of A opposite 8-oxo-G by human replicative DNA pols 
like δ, ε and α at a higher frequency of 10-75%. Two different sub pathways of BER assure 
the complete repair of 8-oxo-G, when C:8-oxo-G mispair is detected on the transcribing 
strand, OOG1 dependent BER pathway is activated, leaving behind a lesion free intact 
DNA. This DNA strand than acts as a transcribing template. When A:8-oxo-G base pair is 
encountered; a MUTYH dependent pathway is stimulated, allowing for the removal of 
adenine. Finally, a key role of MUTYH and DNA pol λ in the repair of 8-oxo-G repair was 
recently shown by van Loon and Hübscher. DNA pol λ null mouse fibroblasts are known to 
be hypersensitive to oxidative DNA damaging agents, suggesting a vital role of DNA pol λ 
in protecting the cells against the cytotoxic effects of oxidative DNA damage (44). 
Auxiliary factors have known to play an important role in lesion bypass. PCNA and RP-A 
allowed correct incorporation of dCTP, opposite an 8-oxo-G template 1,200-fold more 
efficiently than the incorrect dATP by DNA pol λ and 68 fold by DNA pol η (43).  
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Figure 12. Model for MUTYH initiated long patch BER of 8-oxo-G after misincorporation by the 
replication machinery.1) DNA replication over an 8-oxo-G by DNA pol δ. 2.) recognition of an A:8-oxo-G 
mispair by MUTYH, removal of the A and formation of an AP site (denoted as B) 3.) Recruitment of APE1 
mediated by MUTYH/PCNA and generation of 5`-P, 3`-OH gapped intermediate. 4.) Protection of 1-nt gap 
by RP-A and PCNA mediated recruitment of DNA pol λ, with accurate gap filling  (dCTP incorporation) 5.) 
PCNA mediated recruitment of FEN 1 and removal of 1-nt flap. 6.) Ligation of the nick by recruited DNA 
Ligase 1 and futher faithfull OGG1 initiated DNA pol β mediated SP-BER of C:8-oxo-G product. 
Alternatively an inaccurate loop is initiated:(A) DNA pol λ catalyzes inaccurate gap filling.(B) recruitment of 
DNA Ligase III/XRCC1 mediated by PCNA and ligation of the nick. (C) Recognition of A:8-oxo-G mispair 
by MUTYH, remove of A and generation of APE1 mediated by MUTYH/PCNA, generation of 5-P, 3-OH 
gapped intermediate. This creates an opportunity for DNA pol λ to catalyze accurate LP-BER. Reproduced 
from van Loon, B and Hübscher, U, PNAS, 106, 18201-18206 (2009). 
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Abstract 
 
Aging is associated with accumulation of DNA damage and increased incidence of cancer. 
Reactive oxygen species, constantly generated as by-products of cellular metabolism or 
from exogenous sources, readily attack genomic DNA generating mutagenic DNA lesions 
such as 7,8-dihydro-8-oxo-guanine (8-oxo-G), a major contributor to the ageing process. 
Here, we show that the Werner syndrome helicase (WRN), whose deficiency is associated 
with premature aging and cancer susceptibility, is specifically recruited to a DNA duplex 
containing an 8-oxo-G:A mispair in a manner dependent on DNA polymerase λ (DNA pol 
λ), which catalyzes accurate translesion synthesis over 8-oxo-G. Moreover, we demonstrate 
that WRN physically interacts with DNA pol λ and enhances its primer extension activity 
with a preference for DNA templates containing an 8-oxo-G. Experiments in vivo reveal 
that WRN and DNA pol λ colocalize at sites of 8-oxo-G lesions induced by H2O2. In 
addition, we have found that re-localization of WRN to 8-oxo-G lesions is dependent upon 
DNA pol λ. We propose that WRN facilitates the bypass of 8-oxo-G lesions by DNA pol λ 
during repair of 8-oxo-G:A mispairs, thus preventing GC to AT transversions which might 
lead to cancer and premature aging. 
 
 
Introduction 
 
Reactive oxygen species (ROS), that are constantly produced in living organisms as 
byproducts of normal cellular metabolism or as a consequence of environmental exposure 
to various physical and chemical agents, can generate a variety of oxidized DNA bases that 
are highly mutagenic and hence compromise genomic stability and promote carcinogenesis 
{Valko, 2004 #17; Klaunig, 2004 #18; Klaunig,  #19}. One of the most frequent oxidative 
lesions is 7,8-dihydro-8-oxo-guanine (8-oxo-G) with a steady-state level of 4-10 lesions per 
106 DNA bases in normal human tissue {Collins, 1999 #1; Dizdaroglu, 2002 #3}. 
Replication of genomic DNA containing 8-oxo-G lesions frequently leads to the formation 
of 8-oxo-G:A mispairs giving raise to a G:C to A:T transversion mutations {Avkin, 2002 
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#2}. Interestingly, these transversions are the most predominant somatic mutations found in 
lung, breast, ovarian, gastric and colorectal cancers, suggesting that a failure to eliminate 8-
oxo-G lesions can initiate tumorigenesis and drive tumor progression {Greenman, 2007 
#20}. 
 
Oxidized base lesions are primarily eliminated by base excision repair (BER) 
{Hazra, 2007 #26}.  In mammalian cells, the repair of 8-oxo-G:A mispairs is achieved via 
two BER events that occur sequentially on the two DNA strands (reviewed in {van Loon,  
#21}). The first event is initiated by excision of the mispaired A residue by the MutY 
glycosylase homologue (MUTYH) in a reaction coordinated by PCNA {Takao, 1999 #22; 
Hayashi, 2002 #23; van Loon, 2009 #7}. This is followed by cleavage of the apurinic site 
(AP) by the AP endonuclease 1 (APE1) resulting in a DNA intermediate containing a one-
nucleotide gap with a 3’-OH moiety {Yang, 2001 #24; van Loon, 2009 #7}. PCNA and 
RPA then govern the bypass of the 8-oxo-G lesion by the DNA polymerase (pol) λ, which 
in the presence of these two auxiliary factors preferentially incorporates dCMP opposite the 
lesion {Maga, 2007 #6; Maga, 2008 #25; van Loon, 2009 #7}. Following lesion bypass, 
RPA dissociates and PCNA (by binding to FEN1) allows removal of the 5’-single-stranded 
DNA (ssDNA) flap resulting from the strand displacement synthesis by DNA pol λ  {van 
Loon, 2009 #7}. Finally, DNA ligase I interacts with PCNA loaded on the nick arising 
from FEN1 cleavage and seals it, creating the substrate for a second BER event, which 
leads to the elimination of the 8-oxo-G lesion {van Loon, 2009 #7}. 8-oxo-G paired with C 
is predominantly excised by the OGG1 glycosylase in a short patch BER reaction in which 
DNA pol β fills the one nucleotide gap opposite the lesion and the DNA ligase III/XRCC1 
complex finally seals the nick {Hazra, 2007 #26}. However, repair of 8-oxo-G:A mispairs 
in extracts from Ogg1−/− mouse embryonic fibroblasts (MEFs) has been found to proceed 
with a similar efficiency as in wild-type cell extract, suggesting that 8-oxo-G in this two-
step BER pathway might be excised by enzymes other than OGG1 {Dantzer, 2003 #27}. 
 
In the recent past, a number proteins acting in BER, such as NEIL1 {Das, 2007 
#15}, APE1 {Ahn, 2004 #8}, DNA pol β {Harrigan, 2003 #9; Harrigan, 2006 #10}, FEN1 
{Brosh, 2001 #11}, PCNA {Rodriguez-Lopez, 2003 #12} and RPA {Brosh, 1999 #33} 
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have been shown to interact physically and functionally with the WRN 
helicase/exonuclease, which is mutated in Werner syndrome (WS), an autosomal recessive 
disorder characterized by premature aging, cancer predisposition and genomic instability 
{Rossi,  #16}. Interestingly, WRN-deficient cells accumulate 8-oxo-G lesions at a much 
higher rate than WRN-proficient cells, suggesting that WRN plays a role in the cellular 
response to oxidative stress {Das, 2007 #15}. In this work we have considered the 
possibility that WRN might act in the repair of 8-oxo-G:A mispairs. By using human cell 
extracts, we show that WRN is specifically recruited to a DNA duplex containing an 8-oxo-
G:A mispair in a manner dependent on DNA pol λ. Moreover, WRN forms a complex with 
DNA pol λ through direct binding to its pol X core domain and stimulates the bypass of 8-
oxo-G lesions by DNA pol λ. At the cellular level, WRN and DNA pol λ colocalize at sites 
of 8-oxo-G lesions in response to H2O2 treatment. Most importantly, WRN is recruited to 
sites of 8-oxo-G lesions only in the presence of DNA pol λ in the cell. These findings 
provide a strong evidence for a role of WRN in the repair of 8-oxo-G:A mispairs in 
mammalian cells. 
 
 
Results 
 
WRN is Specifically Recruited to DNA Containing an 8-oxo-G:A Mispair in a Manner 
Dependent on DNA Polymerase λ. To explore the role for WRN in the repair of 8-oxo-
G:A mispairs, we employed a reversible cross-linking assay established previously to 
monitor the recruitment of BER proteins to damaged DNA {Parsons, 2004 #44}. A 3′-
biotinylated hairpin loop oligoduplex (27 bp) containing a single 8-oxo-G:A mispair and 
the corresponding lesion-free substrate {van Loon, 2009 #7} were incubated with HeLa 
whole cell extract in the presence of a cross-linking agent and Mg2+. At different time 
points, cross-linked DNA-protein complexes were isolated using streptavidin beads, and 
after reversing the cross-links, bound proteins were analyzed by Western blotting. We 
observed a rapid, damage-specific recruitment of WRN to the DNA substrate (Fig. 1A). A 
robust damage-specific recruitment of DNA pol λ was also detected as previously reported 
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{van Loon, 2009 #7}. These results provide a strong evidence for the involvement of WRN 
in the repair of 8-oxo-G:A mispairs. 
 
 To address the possibility that DNA pol λ was required for the recruitment of WRN 
to the 8-oxo-G:A-containing DNA substrate, whole cell extracts from pol λ-/- and pol λ+/+ 
mouse embryonic fibroblasts (MEFs) were subjected to the crosslinking assay. We found 
that in the absence of DNA pol λ, the binding of WRN to the 8-oxo-G:A substrate was 
impaired, suggesting that DNA pol λ  recruits WRN to the sites of 8-oxo-G:A repair (Fig. 
1B).  
 
 
WRN and DNA Polymerase λ  Interact Physically in Vivo and in Vitro. To examine 
whether WRN and DNA pol λ interact physically, an extract of HEK293T cells expressing 
Myc-tagged DNA pol λ was subjected to immunoprecipitation with anti-WRN antibody. 
We found that DNA pol λ co-immunoprecipitated with WRN in this experiment (Fig. 2A, 
lanes 3-4). In contrast, neither DNA pol λ nor WRN were detected in the 
immunoprecipitate obtained with control IgG (Fig. 2A). Interestingly, the level of WRN-
DNA pol λ complex detected in the extract from cells treated with H2O2 was slightly higher 
than that in the extract from non-treated cells (Fig. 2A, compare lanes 3 and 4), suggesting 
that the formation of this complex might be stimulated by oxidative DNA damage. 
 
To examine whether WRN and DNA pol λ interact directly, we performed a co-
immunoprecipitation experiment with a mixture of purified recombinant proteins. We 
found that WRN and DNA pol λ co-precipitated with anti-WRN antibody, but not with 
control IgG, indicating a direct interaction between these proteins (Fig. 2B). In order to 
quantify the affinity of this interaction, surface plasmon resonance measurements on a 
BIAcore 3000 were carried out. Increasing concentrations of DNA pol λ ranging from 0 
nM to 500 nM, were passed through a biosensor chip coated with WRN (Fig. 2C). 
Evaluation of association and dissociation curves gave an apparent dissociation constant of 
0.4 nM, indicating a strong binding. 
 61 
Next, we used a GST pull-down assay to map the region of WRN binding to DNA 
pol λ. DNA pol λ bound well to GST-WRN949-1432 and GST-WRN500-946, but not to GST-
WRN51-499 or to GST alone (Fig. 2E). These results indicated that DNA pol λ interacted 
with the helicase domain of WRN (amino acids 500-946) as well as with the C-terminal 
region of WRN, which contains winged-helix domain, a binding site of a number of other 
proteins shown to interact with WRN (reviewed in {Lee, 2005 #29}). In order to map the 
WRN-binding site on DNA pol λ, co-immunoprecipitation experiments were performed 
with different deletion variants of DNA pol λ (Fig. 2D). A stable interaction of WRN with 
DNA pol λ244-575, but not with DNA pol λ1-132 and DNA pol λ133-244 was observed, 
suggesting that WRN binds to the catalytic core domain of DNA pol λ (Fig. 2D). 
 
 
WRN Enhances the Bypass of 8-oxo-G Lesions by DNA Polymerase λ .   In order to gain 
insight into the role of WRN in the repair of 8-oxo-G:A mispairs, we next evaluated the 
effect of WRN on the extension by DNA pol λ of a 39-nt primer annealed to a 72-nt 
template containing an 8-oxo-G lesion at the +1 position. WRN exerted a robust 
stimulatory effect on primer extension by DNA pol λ in a reaction being more efficient on 
8-oxo-G template than on a lesion-free template (Fig. 3A and B, lanes 2-6). In contrast, 
stimulation of DNA pol λ was not observed with other RecQ helicases such as BLM and 
RECQ5, suggesting that the observed stimulation was specific for WRN (Fig. 3A and B, 
lanes 2, 7 and 8). Single nucleotide incorporation experiment confirmed that WRN 
facilitated bypass of the 8-oxo-G lesion by DNA pol λ enhancing the incorporation of both 
dCMP and dAMP opposite the lesion (Fig. 3C, lanes 10-18). On the lesion-free template, 
DNA pol λ incorporated only dCMP in the presence of WRN as it did in its absence, 
indicating that WRN does not affect the inherent fidelity of DNA pol λ (Fig. 3C, lanes 1-9). 
To test the specificity of the stimulatory effect of WRN on the primer extension by DNA 
pol λ over 8-oxo-G, four other lesions were tested:  an apurinic site, a 4-methylthymine, a 
6-methylguanine and a cis-platinum adduct. WRN did not stimulate the bypass of these 
lesions by DNA pol λ suggesting that the observed effect over 8-oxo-G is specific 
(Supplementary Fig. S1). 
 62 
To address whether the enzymatic activities of WRN are required for the observed 
stimulation of DNA pol λ, we used previously established mutants of WRN defective either 
in the exonuclease (E84A) or in the helicase (K577M) activity {Huang, 1998 #35; Gray, 
1997 #34}. Both mutants stimulated primer extension by DNA pol λ to the same extent as 
the wild-type WRN on both 8-oxo-G and lesion-free templates (Fig. 3D), suggesting that 
the observed stimulatory effect is due to the physical interaction between DNA pol λ and  
WRN and is not dependent on WRN catalytical activities. 
 
 
WRN and DNA Polymerase λ Colocalize at Sites of Oxidative DNA Damage. To 
evaluate the response of WRN and DNA pol λ to oxidative DNA damage in vivo, we used 
the indirect immunofluorescence technique to study the spatial distribution of these proteins 
in U2OS cells after H2O2 treatment. In agreement with previous reports, WRN was 
observed to localize to the nucleolus in the majority of non-treated cells, whereas DNA pol 
λ showed a dispersed nuclear staining (Fig. 4A, top row). Upon treatment with 500 µM 
H2O2 for two hours, WRN and DNA pol λ each formed >10 distinct foci per nucleus in 
45% and 65% of cells, respectively. Approximately in 30% of cells, WRN foci showed 
complete co-localization with DNA pol λ foci. In the remaining cells, a partial co-
localization between WRN and DNA pol λ was observed. It is known that H2O2 causes not 
only oxidative base damages, but also single-strand and double-strand DNA breaks 
{Benitez-Bribiesca, 1999 #28}. Therefore it is possible that the foci of WRN and DNA pol 
λ that did not colocalize represent sites of other types of DNA damage. 
 
In order to support that WRN and DNA pol λ co-localize at sites of oxidative 
damage, untreated and H2O2-treated cells were co-immunostained either for visualization of 
WRN and 8-oxo-G or for visualization of DNA pol λ and 8-oxo-G. The results indicated 
that WRN and DNA pol λ co-localized with the sites 8-oxo-G damage in ∼40% and ∼50% 
of cells, respectively (Fig. 4B). Collectively, these results provide evidence that WRN and 
DNA pol λ operate in the repair of 8-oxo-G lesions in human cells.  
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DNA Polymerase λ is Required for WRN Recruitment to Sites of 8-oxo-G Lesions in 
Vivo. To further explore the function of WRN and DNA pol λ in the cellular response to 
oxidative DNA damage, WRN was down-regulated in U2OS cells by RNA interference 
and cells were subjected to immunofluorescence staining for DNA pol λ and 8-oxo-G prior 
to and after H2O2 treatment. We found that WRN depletion did not abolish the 
accumulation of DNA pol λ at sites of 8-oxo-G lesions (Fig. 5A). A small increase of DNA 
pol λ foci was observed in WRN-deficient cells relative to WRN-proficient cells even in 
absence of H2O2 (Fig. 5B). This might be due to the elevated level of spontaneous oxidative 
DNA damage previously observed in WRN deficient cells {Von Kobbe, 2004 #14}. 
 
Finally, we compared by immunofluorescence the response of WRN to oxidative 
stress in DNA pol λ+/+ and DNA pol λ-/- MEFs. The results demonstrated that genetic 
ablation of DNA pol λ impaired the recruitment of WRN to sites of 8-oxo-G lesions (Fig. 
5B). Interestingly, in DNA pol λ-/- MEFs, WRN formed numerous foci in response to H2O2 
treatment (data not shown). These most probably represent sites of DNA double-strand 
breaks resulting from processing of oxidative DNA damage. Collectively, our data indicate 
that DNA pol λ is required for the re-localization of WRN to sites of 8-oxo-G lesions. 
 
 
Discussion 
 
The replicative DNA polymerases α, δ and ε have strong tendency to incorporate an 
A opposite an 8-oxo-G leading to a Hoogsteen base pair, which can give rise to GC to AT 
transversion (reviewed in {Hubscher, 2010 #45}). Recent studies in our laboratory have 
advanced the understanding of the molecular mechanism underlying the repair of 8-oxo-
G:A mispairs in mammalian cells {Maga, 2007 #6; Maga, 2008 #25; van Loon, 2009 #7}. 
Cross-linking experiments with human cell extracts and model DNA substrates have 
revealed that MUTYH, DNA pol λ, PCNA, RPA, FEN1 and DNA ligases I or III are 
involved in the excision of the mispaired A nucleotide and its replacement with a dCMP 
{van Loon, 2009 #7}, a BER reaction, which has to take place prior to the removal of the 8-
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oxo-G lesion by the 8-oxo guanine DNA glycosylase (OGG1) (reviewed in {van Loon, 
2010 #21}).  Here we provide evidence that the WRN protein participates in this process by 
serving as an additional auxiliary factor that promotes the bypass of the 8-oxo-G lesion by 
DNA pol λ. We show that WRN physically interacts with DNA pol λ and accumulates at 
sites of 8-oxo-G lesions in a DNA pol λ-dependent manner, suggesting that DNA pol λ 
recruits WRN to the sites 8-oxo-G:A repair. Interestingly, previous studies have shown that 
WRN physically interacts with FEN1 and strongly stimulates FEN1-catalyzed cleavage of 
5’ flap substrates {Brosh, 2001 #11}. This activity is essential to generate a ligateable 3′-
OH end following strand-displacement synthesis by DNA pol λ during the repair of 8-oxo-
G:A mispairs {van Loon, 2009 #7}. Thus, it is possible that, in addition to DNA pol λ  
stimulation, WRN promotes the endonucleolytic cleavage by FEN1 in this BER pathway. 
 
Our study has shown that the helicase and exonuclease activities of WRN are 
dispensable for DNA pol λ stimulation by WRN. Similarly, the functional interaction of 
WRN with FEN1 was independent of the WRN catalytic functions {Brosh, 2001 #11}. 
These findings suggested that the stimulatory effect of WRN on these enzymes stems from 
direct protein interaction. It is possible that physical interaction between WRN and DNA 
pol λ triggers a conformational change in the polymerase, which alters its catalytic 
properties. Interestingly, the domain of WRN that mediates the functional interaction 
between WRN and FEN1 resides within the C-terminal portion of WRN that also mediates 
interaction with DNA pol λ {Brosh, 2001 #11}. It will be interesting to examine whether 
this domain, referred to as winged-helix domain, plays a role in the stimulatory effect of 
WRN on DNA pol λ. 
 
Like WRN, PCNA has also been found to interact with the catalytic domain of 
DNA pol λ and enhance its primer extension activity on lesion-free and 8-oxo-G-containing 
DNA templates. {Shimazaki, 2002 #42; Maga, 2002 #38; Maga, 2007 #6}. However, the 
mechanism of PCNA action seems to differ from that of WRN. PCNA was found to 
increase the processivity of DNA pol λ possibly by stabilizing its binding to the 
template/primer junction {Maga, 2002 #38}. In contrast, WRN appears to enhance the 
catalytic activity of DNA pol λ in general and its translesion DNA synthesis in particular. 
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WRN, however, stimulated the incorporation of both dCMP and dAMP opposite the 8-oxo-
G lesion to a similar degree. In contrast, PCNA was found to increase the incorporation 
rates of dCMP opposite an 8-oxo-G, but not of dAMP incorporation opposite the lesion. 
The faithful incorporation of dCTP was enhanced about 100 times when the optimal 
concentrations of PCNA and RPA were used either in a standing start primer extension 
over 8-oxo-G {Maga, 2007 #6} or by repairing a one nucleotide gap containing an 8-oxo-G 
{Maga, 2008 #25}. A similar selectivity by DNA pol λ in the presence of PCNA and RPA 
was also found when the MUTYH DNA glycosylase and APE1 removed an incorrect A 
incorporated by DNA pol δ {van Loon, 2009 #7}. In a next step, it will be interesting to 
explore the role of WRN in the reconstituted 8-oxo-G:A repair system recently established 
in our laboratory{van Loon, 2009 #7}.   
 
It was reported that WRN could also stimulate DNA synthesis by the human DNA pol δ 
{Kamath-Loeb, 2000 #39} and by the Y-family translesion (TLS) pols η, ι and κ, whereas 
it did not affect the synthesis by DNA pols α, β and ε {Kamath-Loeb, 2007 #40}. As in the 
case of DNA pol λ, the stimulation of Y-family DNA pols was found to be specific to 
WRN since no stimulation was observed with other RecQ family members such as BLM or 
E. coli RecQ {Kamath-Loeb, 2007 #40}. WRN could also promote lesion bypass by TLS 
pols in a manner dependent on type of lesion. For example, addition of WRN to limiting 
amounts of DNA pol η stimulated primer extension activity on templates containing a 
cyclobutane pyrimidine dimer (CPD) or an 8-oxo-G, whereas only limited lesion bypass of 
methyl adducts was observed with DNA pol η {Kamath-Loeb, 2007 #40}. Similarly, we 
found that WRN stimulated DNA pol λ to bypass 8-oxo-G, but not an apurinic site, 4-
methylthymine, 6-methylguanine and cisplatin. Most importantly, the extension activity of 
DNA pol η on CPD- and 8-oxo-G-containing templates was comparable with that observed 
on lesion-free DNA template. In contrast, we found that WRN increased primer extension 
activity of DNA pol λ on 8-oxo-G template more efficiently than on lesion-free template, 
suggesting a specific interaction of WRN with DNA pol λ during the 8-oxo-G during lesion 
bypass. 
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WRN deficiency has been found to be associated with a defect in cell proliferation 
arrest in response to oxidative stress and with accumulation of 8-oxo-G and Fapy-G lesions 
in the genomic DNA {Von Kobbe, 2004 #14; Das, 2007 #15}. Inherited mutations in the 
WRN gene cause Werner syndrome that is characterized by premature aging and cancer 
predisposition, phenotypes arising from persistent oxidative stress to genomic DNA {Rossi,  
#16; Maynard, 2009 #5}. Our work adds significant insight into the basis of these 
phenotypes and further highlights the importance of WRN for oxidative damage repair in 
mammalian genomes. 
 
 
Materials and Methods 
 
Antibodies and Proteins. Affinity purified rabbit polyclonal antibodies against human 
DNA pol λ and WRN were described previously {van Loon, 2009 #7; Saydam, 2007 #31}. 
Antibody against mouse DNA pol λ was a gift from G.L. Dianov (University of Oxford). 
Mouse monoclonal anti-WRN antibodies were purchased from BD Biosciences (cat. # 
611169; used for immunobloting) and Abcam (ab 66601, used for immunofluorescence 
staining). Mouse monoclonal antibody against 8-oxo-G was purchased from Millipore 
(MAB3560, clone 483.15). Rabbit polyclonal antibodies against Myc-tag and TFIIH were 
from Santa Cruz. Recombinant human DNA pol λ protein was expressed and purified as 
described {Ramadan, 2003 #36}. His-tagged recombinant human DNA pol λ fragments 
were purified on Ni-NTA agarose (Invitrogen) as recommended by the manufacturer. 
Recombinant human WRN protein and its mutants were produced and purified as 
previously described {Orren, 1999 #30}. These protein preparations did not contain any 
contaminating DNA polymerase activity (Supplementary Fig. S2). RECQ5 and BLM 
proteins were purified as previously described {Garcia, 2004 #46; Kanagaraj, 2006 #47}.  
 
 
Cell Culture Experiments. All cell lines (HeLa, U2OS, HEK293T, MEFs) used in this 
study were maintained in DMEM (Gibco) supplemented with 10 % fetal calf serum (Gibco) 
and streptomycin/penicillin (100 U/ml). Where required, H2O2 (Sigma) was diluted using 
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DMEM and added to cell cultures to a final concentration of 500 µM. Transfection of 293T 
cells with pcDNA3 vector expressing Myc-tagged human DNA pol λ {Wimmer, 2008 #32} 
was done using Metafectene (Biontex) according to manufacturer’s instructions. 
Transfection of siRNA oligonucleotides was carried out using Lipofectamine RNAiMAX 
(Invitrogen) according to manufacturer’s instructions. Cells were analyzed 72 hours after 
siRNA transfection. 
 
 
Immunoprecipitation Assays. Total cell extract preparation and immunoprecipitation (IP) 
were carried out as described previously {Saydam, 2007 #31}. Briefly, cell extracts (1.5 mg 
of protein) pre-treated with DNaseI (Roche) were incubated overnight at 4°C either with 
purified rabbit polyclonal anti-WRN IgGs (2 µg) or with IgGs purified from preimmune 
serum (2 µg). Mixtures were then incubated for 1.5 hours at 4°C with Protein A/G-agarose 
beads (20 µl; Santa Cruz). After extensive washing, the immune complexes were eluted 
from beads by heating at 95°C for 10 minutes in 2x Laemmli SDS buffer. The obtained 
immunoprecipitates were subjected to Western blot analysis. The blots were probed with 
appropriate antibodies and immune complexes were detected using the ECL-plus reagent 
(GE Healthcare). For IP of purified recombinant proteins, a mixture of equal amounts of 
WRN (500 ng) and DNA pol λ (500 ng) was incubated for 2 hours at 4°C and then added to 
Protein A/G-agarose beads (20 µl) coated with rabbit polyclonal anti-WRN IgGs (2 µg). 
After incubation for 2 hours at 4°C, the beads were washed and subjected to Western blot 
analysis.  
 
 
Immunofluorescence Assays. Cells cultured on coverslides were fixed with 3.7% 
formaldehyde for 10 minutes at room temperature (RT) and subsequently permeabilized by 
soaking in 0.2% (v/v) Triton X-100 for 5 minutes at RT. After blocking in PBS containing 
5 mg/ml BSA for 30 minutes at RT, the fixed cells were incubated overnight at 4°C with 
appropriate primary antibodies. All antibodies were diluted in blocking solution: rabbit 
polyclonal anti-WRN antibody (1:500), rabbit polyclonal anti-DNA pol λ (1:500) and 
mouse monoclonal anti-WRN antibody (Abcam, 1:50). The slides were washed with PBS 
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and incubated for 1.5 hour at RT with secondary antibodies diluted in blocking solution: 
FITC-conjugated sheep anti-rabbit IgG (Sigma; 1:700) and Texas Red-conjugated donkey 
anti-mouse IgG (Jackson Immunoresearch, 1:200). After washing with PBS, coverslips 
were mounted on Vectashield (Vector Laboratories) and images were captured by an 
Olympus IX81 fluorescence microscope. At least 100 nuclei were analyzed in each 
experiment. 
 
For simultaneous detection of WRN and 8-oxo-G, cells were fixed and sequentially 
incubated with rabbit polyclonal anti-WRN antibody and anti-rabbit FITC conjugated 
secondary antibody. Stained cells were then fixed with 100% cold methanol for 30 minutes 
at -20°C and immersed in 100% cold acetone for 30 seconds. After washing, the fixed cells 
were treated with 2M HCl for 30 minutes to denature the DNA and then neutralized with 
0.1 M borate buffer (pH 8.5). After washing and blocking, cells were stained with mouse 
monoclonal anti-8-oxo-G (IgM) antibody (1:100) followed by Texas Red-conjugated 
donkey anti-mouse IgM secondary antibody (Jackson Immunoresearch, 1:150). After 
washing, coverslips were mounted and analyzed as described above. The same procedure 
was used for simultaneous detection of DNA pol λ and 8-oxo-G lesion.    
 
 
GST Pull-Down Assays. GST pull-down assays were performed as previously described 
{Saydam, 2007 #31}. Briefly, bacterially expressed GST-WRN fusion proteins were bound 
to glutathione-Sepharose beads (20 µl; GE Healthcare) and incubated with 0.5 µg of 
recombinant human DNA pol λ for 2 hours at 4°C. After extensive washing, bound 
proteins were analyzed by Western blotting. Glutathione beads coated with GST-protein 
only were used as control. 
 
 
Surface Plasmon Resonance measurements. The kinetics of binding of the human DNA 
pol λ to WRN was measured at 25°C using a BIAcore 3000 instrument (GE Healthcare). A 
total of 1000 resonance units (RU) of WRN were immobilized on a research grade CM5 
chip (Bio core TM). Different concentrations of purified human DNA pol λ (0-500 nM) 
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were injected at 20 µl/min across the sensor surface. Data analysis was performed with the 
BIAevalution software (Pharmacia, version) (see SI Text). 
 
 
Cross-linking Assay. DNA-protein cross-linking assays with cell extracts and hairpin 
oligonucleotide substrates attached to streptavidin magnetic beads (Invitrogen) were 
performed as described previously {van Loon, 2009 #7}. Reactions were carried out in the 
presence of Mg2+ over different periods of time ranging from 0.25 to 4 minutes. Each 
reaction contained 100 µg of protein. 
 
 
Primer Extension Assay. Annealing of 72mer containing 8-oxo-G lesion (or a normal G) 
with the 5’-[32P]-labeled 39mer primer created a primer/template substrate with the lesion 
(or a normal G) at the +1 position relative to single-strand/double-strand junction (see SI 
text for sequences of the oligonucleotides). The reaction mixtures (10 µl) contained 50 mM 
Tris-HCl (pH 7.5), 2 mM DTT, 0.25 mg/ml BSA, 10 µM dNTP, 1 mM MgCl2 and 10 fmol 
of the 5’[32P]-labeled primer/template substrate. Concentrations of human DNA pol λ and 
human WRN are indicated in figures and figure legends. Reaction mixtures were separated 
on a denaturing urea-polyacrylamide gel and radiolabeled DNA species were visualized by 
autoradiography.  
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Figure Legends 
 
Fig. 1. Recruitment of WRN to a DNA duplex containing an 8-oxo-G:A mispair is 
dependent DNA pol λ. (A) DNA-protein cross-linking assay using 8-oxo-G:A (Left panel) 
or G:C (Right panel) hairpin DNA substrates and HeLa whole-cell extract. (B) DNA-
protein cross-linking assay using 8-oxo-G:A hairpin substrate and whole cell extracts from 
DNA pol λ-/- (Left panel) or DNA pol λ+/+ (Right panel) mouse embryonic fibroblasts. The 
experiments were performed under the conditions specified in Materials and Methods. 
Blots were probed with mouse monoclonal anti-WRN and rabbit polyclonal anti-DNA pol 
λ antibody. 
 
 
Fig. 2. WRN and DNA pol λ physically interact. (A) Co-immunoprecipitation of DNA pol 
λ with WRN from extracts of non-treated and H2O2-treated HEK293T cells. Cells were 
transiently transfected with plasmid expressing Myc-tagged DNA pol λ and, 48 hours post 
transfection, treated with 500 µM H2O2 for 2 hours or mock-treated. WRN was 
immunoprecipitated using rabbit polyclonal anti-WRN antibody as described under 
Materials and Methods. Blots were probed with rabbit polyclonal anti-Myc antibody and 
mouse monoclonal anti-WRN antibody. Lane 2, control immunoprecipitatate obtained with 
preimmune rabbit IgGs. (B) Co-immunoprecipitation of DNA pol λ with WRN from a 
mixture of purified proteins (300 ng of each protein) pre-incubated on ice for 2 hours. Blots 
were probed as in (A). (C) Analysis of WRN binding to DNA pol λ using BIAcore 3000. 
An overlay plot of sensograms obtained by injection of indicated concentrations of DNA 
pol λ over a CM-5 chip coated with WRN is shown. (D) Mapping of WRN-interacting 
domain of DNA pol λ. (Top panel) Domain organization of DNA pol λ. NLS, nuclear 
localization sequence; BRCT, BRCA1 C-terminal domain; Ser/Pro, serine/proline rich 
domain; Pol X domain, catalytic domain conserved in the X family of DNA pols. Black 
lines indicate fragments used for mapping. (Bottom panel) Co-immunoprecipitattion assay. 
Purified (His)6-tagged DNA pol λ fragments were incubated with full-length WRN 
followed by immunoprecipitation with rabbit polyclonal antibody against WRN or with 
control (Ctrl) IgG. Immunoprecipitates were analyzed by Western blotting as in (A). IB, 
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immunoblot. (E) Mapping of the DNA pol λ-interacting domain of WRN. (Top panel) 
Domain organization of WRN. Exo, Exonuclease domain; DExH, helicase domain 
conserved in the DExH family of helicases; RQC, RecQ C-terminal domain composed of 
Zn-binding (Zn) and winged-helix (WH) subdomains; HRDC, helicase and RNase D C-
terminal domain. The black lines indicate WRN fragments used. (Bottom panel) GST pull-
down assay. The indicated WRN fragments were produced as fusions with GST and 
immobilized on glutathione beads. Binding of purified recombinant DNA pol λ to the beads 
was analyzed by Western blotting. The Coomassie Brilliant Blue-stained gel from SDS-
PAGE analysis of the GST-WRN fragments isolated on glutathione beads is also shown. 
Asterisks indicate the GST-WRN fragments. The additional protein bands correspond to 
proteolytic degradation products as determined by immunoblotting using an anti-GST 
antibody. Lane 1, 20% of input of DNA pol λ. 
 
 
Fig. 3. WRN stimulates 8-oxo-G bypass by DNA pol λ. (A) Extension by DNA pol λ of a 
5′-end-labeled 39-nt DNA primer annealed to a 72-nt undamaged control DNA template in 
the presence of indicated concentrations of WRN, BLM and RECQ5, respectively. 
Individual dNTPs were present at a concentration of 10µM. Lane 1, control reaction in the 
absence of dNTPs. (B) As in (A) except that the DNA template contains a single 8-oxo-G at 
position +1. (C) Single nucleotide incorporation by DNA pol λ on the control and 8-oxo-G 
templates as shown in A and B. Reactions were carried out in the absence and in the 
presence of 10 nM WRN as indicated. Lane 1 control reaction in the absence of dNTPs. (D) 
Primer extension by DNA pol λ in the presence of helicase-deficient (K-WRN) and 
exonuclease-deficient (N-WRN) mutants of WRN. The DNA substrates used were the 
same as in (A) and (B), respectively. Reactions in (A-D) were carried out and analyzed as 
specified under Materials and Methods. 
 
 
Fig. 4. WRN and DNA pol λ co-localize at sites of 8-oxo-G lesions in human cells. (A) 
WRN colocalizes with DNA pol λ after exposure of U2OS cells to oxidative stress. Cells 
grown on cover slides were either left untreated or treated with 500 µM H2O2 for 2 hours. 
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After treatment, cells were fixed and immunostained using anti-DNA pol λ (green) and 
anti-WRN (red) antibodies. DAPI staining of the nucleus is shown in blue. (B) WRN and 
DNA pol λ are recruited to sites of 8-oxo-G lesions. U2OS cells were left either non-treated 
(Top panels) or treated with 500 µM H2O2 for 2 hours (Lower panels), fixed and co-stained 
either with anti-WRN (green) and anti-8-oxo-G (red) antibodies or with anti-DNA pol λ 
(green) and 8-oxo-G (red) antibodies under conditions described in Materials and Methods. 
Images were captured on an Olympus IX81 fluorescence microscope 
 
 
Fig. 5. WRN localization to sites of 8-oxo-G lesions in vivo is dependent on DNA pol λ. 
(A) Western blot analysis of extracts of U2OS cells transfected with WRN siRNA (siWRN) 
and control siRNA (siCtrl), respectively. Cells were harvested 72 hours post-transfection. 
Blots were probed with antibodies against WRN, DNA pol λ and TFIIH (loading control). 
(B) Graph showing the proportion of siCtrl and siWRN cells positive for colocalization 
between DNA pol λ and  8-oxo-G foci after mock- and H2O2-treatment. Cells were treated 
with 500 µM H2O2 (or mock-treated) for 2 hours, fixed and immunostained to visualize 
WRN and 8-oxo-G. Treatment was carried out 72 hours after siRNA transfection. (C) 
Western blot analysis of extracts from DNA pol λ+/+ and DNA pol λ-/- mouse embryonic 
fibroblasts (MEFs). Blots were probed with antibodies against WRN, DNA pol λ and β-
tubulin (loading control). The arrowhead indicates the band corresponding to mouse DNA 
pol λ. (D) Graph showing the proportion of DNA pol λ+/+ and DNA pol λ-/- MEFs positive 
for co-localization of WRN and  8-oxo-G foci after mock- and H2O2-treatment, 
respectively. H2O2 was present at a concentration of 100 µM for 2 hours. After treatment, 
cells were fixed and stained for WRN and 8-oxo-G. The data points in (A) and (B) represent 
the mean of three independent experiments with at least 100 nuclei counted in each 
experiment. IB, immunoblot. 
 
 
 77 
Supplementary Information 
 
 
Supplementary Materials and Methods 
 
DNA Substrates and siRNA. Oligonucleotides used for primer extension assays were 
purchased from Purimix and purified by denaturing PAGE. The sequences are: 
72-mer template:  
3′-ATGTTGGTTCTCGTATGCTGCCGGTCACGGCTTAAGTGTXGCGGCCGCG 
GTTGGAGGGCTTATAGATTATG-5′; the bold letter X denotes G, 8-oxo-G, abasic site, 
4-methylthymine or 6-methylguanine. 
60-mer template: 
3′-ATGTTGGTTCTCGTATGCTGCCGGTCACGGCTTTTCTTGGTTCCTATCGG 
TGGTTAGTCG-5′; the 60-mer template containing a single cis-platinum adduct on the G 
residues indicated in bold was prepared as described {Hoffmann, 1995 #37}. 
The underlined sequences correspond to the primer annealing sites. The primers were 5′-
end labeled with T4 polynucleotide kinase and γ[32P]ATP (GE Healthcare) mixed with 
appropriate template oligonucleotide at 1:1 (M/M) ratio in the presence of 20 mM Tris-HCl 
(pH 7.4) and 150 mM NaCl, heated at 95°C for 10 minutes and then slowly cooled down to 
room temperature. 
 All siRNA oligoduplexes used in this study were purchased from Microsynth. The 
sequences of the top strands of these duplexes are shown below: 
siWRN: 5’-UAGAGGGAAACUUGGCAAA-3’ 
siCtrl: 5’-CGU ACG CGG AAU ACU UCG A-3’ 
 
 
Surface Plasmon Resonance Measurements. All binding experiments were performed on 
a Biacore 3000 apparatus (Biacore, GE Healthcare) at 25°C in running HBS buffer (10 mM 
Hepes (pH 7.5), 150 mM NaCl, 3 mM EDTA and 0.005% P20 surfactant). A total of 1000 
resonance units (RU) of WRN helicase (ligand) were immobilized on a research grade 
CM5 biosensor chip (BIAcoreTM) in 10 mM sodium acetate (pH 3.0) according to the 
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manufactures amine coupling kit. The un-reacted residues on the surface were blocked by 
washing with 1M ethanolamine (pH 8.5). One flow cell left blank was used as reference 
cell. Different concentration of DNA pol λ were prepared in HBS running buffer and 
injected at 20 µl/min across the sensor surface. The surface was regenerated by a 30 sec 
pulse of 10 mM glycine followed by a 30 sec pulse of 100 mM HCl and 0.01% SDS at a 
flow rate of 35 µl/min. The signal changes on the activated/blocked control channel were 
subtracted from the WRN-DNA pol λ binding interaction and the subtracted sensogram 
were analyzed.   Injections were performed for each protein concentration. Sensograms 
were evaluated kinetically using BIAcore Evaluation Software. 
 
 
Supplementary References 
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Supplementary Figure Legends. 
 
Fig. S1. WRN has no effect on primer extension by DNA pol λ on DNA templates 
containing apurinic site, 4-methylthymine, 6-methylguanine or cis-platinum. The 
experiments were performed as described in Materials and Methods. DNA pol λ-catalyzed 
extension of a 5’-[32P]-labeled 39-nt DNA primer annealed to 72-nt templates containing 
base lesions as indicated. Reactions were carried out in the absence or in the presence of 
indicated concentrations WRN. Lanes 1, 6, 11 and 16, control reactions carried out in the 
absence of DNA pol λ and WRN (no enzyme control). AP, apurinic site. 
 
 
Fig. S2. Preparations of WRN and its mutants used in this study do not contain a 
contaminating DNA polymerase activity. Primer extension assay was carried out as 
described in Materials and Methods using the lesion-free template. WRN and its mutants 
were present at a concentration of 8 nM. DNA pol λ was 6 nM. 
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